Journal of Medicinal Chemistry

Article

Subscriber access provided by University of South Dakota

(R)-N-(1-Methyl-2-hydroxyethyl)-13-(S)-methylarachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes

 Yingpeng Liu, Lipin ji, Marsha Eno, Shalley Kudalkar, Ailing Li, Marion Schimpgen, Othman Benchama, Paula Morales, Shu Xu, Dow P. Hurst, Simiao Wu, Khadijah A Mohammad, JodiAnne T Wood, Nikolai Zvonok, Demetris Papahatjis, Han Zhou, Chandrashekhar Honrao, Ken Mackie, Patricia H. Reggio, Andrea Hohmann, Lawrence J. Marnett, Alexandros Makriyannis, and Spyros P. Nikas *J. Med. Chem.*, Just Accepted Manuscript • DOI: 10.1021/acs.jmedchem.8b00611 • Publication Date (Web): 10 Sep 2018 Downloaded from http://pubs.acs.org on September 10, 2018

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

..... Grivedicin

(*R*)-*N*-(1-Methyl-2-hydroxyethyl)-13-(*S*)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes

Yingpeng Liu,^{†,+} Lipin Ji,^{†,+} Marsha Eno,[†] Shalley Kudalkar,[‡] Ailing Li,[£] Marion Schimpgen,[#] Othman Benchama,[†] Paula Morales,^{§4} Shu Xu,[‡] Dow Hurst,[§] Simiao Wu,[†] Khadijah A. Mohammad,[†] JodiAnne T. Wood,[†] Nikolai Zvonok,[†] Demetris P. Papahatjis,[#] Han Zhou,[†] Chandrashekhar Honrao,[†] Ken Mackie,[£] Patricia Reggio,[§] Andrea G. Hohmann,[£] Lawrence J. Marnett,[‡] Alexandros Makriyannis,^{*,†,□} Spyros P. Nikas.^{*,†}

⁺equal contribution

[†]Center for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.

^DDepartments of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States.

[‡]Departments of Biochemistry, Chemistry, and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.

[£]Department of Biological and Brain Sciences, Indiana University, Bloomington, Indiana 47405, United States.

[#]Institute of Organic and Pharmaceutical Chemistry, National Hellenic Research Foundation, 48 Vass. Constantinou, Athens 116-35, Greece.

[§]Center for Drug Discovery, Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina 27402, United States.

*To whom correspondence should be addressed.

ABSTRACT

The synthesis of potent metabolically stable endocannabinoids is challenging. Here we report a chiral

arachidonoyl ethanolamide (AEA) analog, namely, (13S, 1'R)-dimethylanandamide (AMG315, 3a) a

high affinity ligand for the CB1 receptor (Ki of 7.8 ± 1.4 nM) that behaves as a potent CB1 agonist in

vitro (EC₅₀ = 0.6 \pm 0.2 nM). (13S, 1'R)-dimethylanandamide is the first potent AEA analog with

significant stability for all endocannabinoid hydrolyzing enzymes as well as the oxidative enzymes

COX-2. When tested *in vivo* using the CFA-induced inflammatory pain model **3a** behaved as a more

potent analgesic when compared to endogenous AEA or its hydrolytically stable analog AM356. This

novel analog will serve as a very useful endocannabinoid probe.

INTRODUCTION

The endocannabinoids (eCBs) N-arachidonoylethanolamine (1a, AEA, Figure 1) and 2arachidonovlglycerol (1b, 2-AG) are endogenously produced lipid-like substances that modulate the effects of the cannabinoid receptors CB1 and CB2, two well recognized drug targets.¹ AEA behaves as a low-efficacy agonist for CB1 and exhibits modest affinity for CB2. It has also been reported that AEA interacts with vanilloid receptors.¹ 2-AG is a high-efficacy agonist at both CB1 and CB2 and appears to be the principal endocannabinoid involved in the rapid modulation of CB1/CB2 function in CNS.¹ AEA and 2-AG are short lived as they are hydrolytically deactivated by enzymes. Fatty acid amide hydrolase (FAAH) breaks down and inactivates AEA while monoacylglycerol lipase (MGL) is the major enzyme responsible for 2-AG hydrolysis.¹ However, FAAH and a brain hydrolase (α/β hydrolase domain-containing 6, ABHD6) can also inactivate 2-AG.¹⁻² Additionally, the eCBs are metabolized by oxygenases including cyclooxygenases (COX-2), lipooxygenases (LOXs) and cytochrome P450 enzymes leading to eicosanoid products with distinct, non CB-mediated, biological actions.³⁻⁴ COX-2 is constitutively expressed in neurons and radial glia and is upregulated in inflammatory situations where it plays a major role in eCB metabolism.⁴⁻⁵ A common feature of the major oxidative metabolic pathways of the eCBs is the abstraction of a hydrogen atom from the methylene groups at C7, C10 and C13. 3

The four pharmacophoric regions within the structures of AEA and 2-AG (Figure 1) encompass a polar head group, a tetraolefinic chain (TC), an *n*-pentyl tail and a linker which connects the head group with the TC.⁶ Of these, the flexible TC is the major determinant of the biologically active conformation(s) of the eCBs as reflected in their binding motifs and G-protein signaling properties.⁶⁻⁹ A key structural feature of the TC is the bis-allylic carbons (7, 10 and 13), that are the carbons connected to two consecutive C=C double bonds. These methylene groups can access a broad region of conformational

space⁹ with the TCs exhibiting a high degree of flexibility. This situation permits the arachidonovl moiety of the lipid to assume a number of conformations including both folded as well as extended conformations.⁹ Studies on AEA and its analogs have suggested that the folded U-, J-, or helical-shaped conformations are responsible for CB1 receptor recognition^{7, 9-11} and successful modifications at the polar head, linker and tail groups of the AEA have been reported with the best-known being the (R)methanandamide (AM356),^{9, 12-16} a valuable AEA analog which exhibits enhanced stability for FAAH. However, ethanolamides with structurally modified or constrained TCs that mimic the above types of conformations are either inactive, or exhibit much lower affinities for the CB1 receptor when compared to AEA.^{8, 11, 15, 17} Worthy of note, ethanolamides with significant affinities for CB2 have not been reported, and there are no reports on AEA analogs that are stable with the major oxidative enzyme COX-2. Recently, we reported the crystal structures of the CB1 receptor.^{7, 18} This breakthrough work in combination with biophysical methods,¹⁹⁻²⁰ computational studies and currently available biochemical and in vivo assays opens the door to explore the molecular basis regarding the bioactive eCB conformation(s) as well as downstream signaling events that are associated with the *in vitro* and *in vivo* pharmacological profiles of these lipids. Taking into consideration all the above, we report here the discovery of novel chiral AEA probes that encompass TCs with distinct conformational properties, higher binding affinities for CB1 and CB2 receptors, increased abilities to activate their molecular targets (CB1, CB2), and enhanced stabilities for their deactivating enzymes FAAH and COX-2. Our lead analog, namely, (13S, 1'R)-dimethyl-anandamide (3a) is a novel chiral eCB ligand possessing high affinity and potency for the CB1 receptor coupled with excellent biochemical stability for FAAH, MGL, ABHD6 and COX-2. This analog suppressed CFA-induced mechanical allodynia through a CB1 mechanism and produced greater anti-allodynic efficacy than its hydrolytically stable analog AM356.

RESULTS AND DISCUSSION

Ligand Design

A very useful approach for the design of the novel AEA analogs with variable conformational and stability properties is the addition of chiral methyl groups in each of the three C7, C10 and C13 bisallylic carbons of AEA (Figure 2). The value of this approach was initially recognized by our preliminary finding that addition of a methyl group at the 13S position of AEA led to an enhanced affinity for the CB1 receptor.⁶ Our first structure-activity/-stability study in which we introduced chiral methyl groups in the bis-allylic carbons of AEA led to chiral Me-arachidonoyl ethanolamides (chiral-Me-AEAs, 2). We showed that when methyl groups with preferred chiralities were introduced at the C7 or C13 positions enhanced the affinities of these analogs for CB1 and CB2 while the C10 methyl analogs were inactive. Subsequently, the most promising analogs (C13- and C7-chiral-Me-AEAs) were modified at the polar head and tail groups to further probe CB receptor recognition in tandem with increasing the stability of the amide group for FAAH. This was pursued through two design approaches. First, we preserved the recognition features of the endogenous ethanolamide head and, as in our earlier work,^{15, 21} we added a second chiral methyl alpha to the nitrogen atom. Second, we replaced the ethanolamine group of our lead (13S)-Me-AEA (2a) with amine groups, including bulky amines, that lack the hydroxyl group of the prototype. These design approaches led to chiral di-Mearachidonoyl ethanolamides (chiral-di-Me-AEAs, 3) and (13S)-Me-arachidonoyl amides [(13S)-Me-AAs, 4].

Chemistry

Based on our preliminary studies,^{6, 17, 22} our optimized synthetic strategy involves key methyl ester precursors (**5**, Figure 3) from which the chiral AEA probes are produced through peptide coupling. The

retrosynthetic analysis disconnects each compound at the double bonds adjacent to the chiral centers by retro-Wittig-type reactions leading to the chiral aldehyde fragments, the head group fragments, and the tail fragments. The strategy was successfully executed after securing these fragments in stereochemically pure form by acetylene alkylation and selective P-2 nickel hydrogenation. Notable is the robustness of the optimized multi-step enantioselective syntheses that allow the synthesis of the final compounds in substantial quantities as needed for further *in vitro* and *in vivo* studies.

Synthesis of the chiral aldehydes **8a** and **8b** was carried out using a modification of our earlier reported procedure²² that improved the overall yields and reduced the synthetic steps (Scheme 1). Thus, silylation of commercially available methyl esters **6a** and **6b** gave the respective TBDPS ethers **7a** and **7b** in excellent yields (97-98%). The subsequent reduction with diisobutylaluminum hydride took place at -110°C using 1.2 equivalents of the DIBAL-H reagent and led to aldehydes **8a** and **8b** in high yields (87-88% after purification) while the formation of the overreduction byproducts alcohols was substantially suppressed (3-5%).

Synthesis of the alkenyl phosphonium salt **14** which is required for the construction of the chiral C7-Me AEA analogs is depicted in Scheme 2. Copper mediated cross-coupling of 3-butyn-1-ol (**9**) with commercially available bromide **10** afforded diyne alcohol **11** in 93% yield. Partial hydrogenation of **11** over P-2 nickel catalyst gave the corresponding skipped Z diene alcohol **12** in 96% yield.^{6, 22} Reaction of triphenylphosphine and carbon tetrabromide with alcohol **12** under mild conditions produced bromide **13** (94% yield). Heating **13** (70-75°C) with dry PPh₃ under an argon atmosphere for five days afforded the phosphonium salt **14** in 90% yield.^{6, 22} The four protons of the two double bonds in compound **14** are well separated in the ¹H NMR spectrum and the coupling constants ³J_{3H-4H} and ³J_{5H-6H} were found to be less than 10.7 Hz. This confirms a Z stereochemistry between the hydrogens in the 3H-4H and 6H-7H spin systems.

The assembly of the triphenylphosphonium bromides 14 and 15 (commercially available) with chiral aldehydes 8a and 8b into (7R)- and (7S)-Me-AEAs 2e and 2f, respectively, is outlined in Scheme 3. Thus, exposure of 15 to potassium bis(trimethylsilyl)amide at room temperature and reaction of the resulting ylide with aldehydes 8a and 8b at -115°C gave the carboxylic acid derivatives 16a and 16b, respectively (73-75% yields). Based on ¹H NMR data this Wittig reaction gave exclusively the Z alkenes with ${}^{3}J_{5H-6H} \sim 10.7$ Hz. Exposure of 16a and 16b to TMSCHN₂ in Et₂O/MeOH esterified the carboxylic acid group leading to methyl esters **17a** and **17b**, respectively.^{17, 22} This was followed by removal of the TBDPS group using TBAF to give **18a** and **18b** in 73-75% yields for the two steps. Dess-Martin periodinane oxidation of alcohols 18a and 18b led to aldehydes 19a and 19b, respectively. Due to their labile character these intermediates were used immediately in the subsequent Wittig olefination reaction with phosphonium salt 14 to give the respective (7R)- and (7S)-methyl arachidonates **20a** and **20b** in very good yields (69-71%) from alcohols **18a** and **18b**. In agreement with our earlier work on similar systems as well as prostaglandin analogs this final Wittig olefination reaction is stereoselective and installs the C8=C9 double bond with the Z stereochemistry.^{6, 17, 22-23} Saponification of 20a and 20b (LiOH in THF/H₂O) afforded acids 21a and 21b (94-96% yields), that were coupled with 2-(tert-butyldiphenylsilyloxy)ethanamide 23 to afford the silylated amide precursors 24a and 24b in excellent yields (95-97%) by using the N,N'-carbonyldiimidazole-mediated amide coupling.^{17, 22} Deprotection of the tert-butyldimethylsilyl ether was carried out by using TBAF in THF and gave the enantiomeric (7R)- and (7S)-methyl anandamides 2e and 2f, respectively, in 85-88% yields.

The enantioselective syntheses of (10S)-, (10R)-, and (13S)-methyl-anandamides **2c**, **2d** and **2a**, respectively, (Figure 2) were reported earlier from our group.^{6, 22} The synthesis of the (13R)-methyl-anandamide **2b** is summarized in Scheme 4 and starts from the phosphonium salt **25**. This advanced

key intermediate is common for the synthesis of all (13S)- and (13R)-methyl substituted AEA analogs and it was synthesized in multigram quantities in eight steps starting from commercially available 3butyn-1-ol as we described earlier.⁶ Wittig olefination of aldehyde **8b** with **25** at low temperature, in the presence of potassium bis(trimethylsilyl)amide, produced exclusively the desired Z-alkene product 26 in excellent yield (91%, ${}^{3}J_{11H-12H} = 10.8$ Hz). This was followed by fluorodesilylation employing TBAF in THF and gave alcohol 27 in 91% yield. Mild oxidation of 27 with the Dess-Martin periodinane reagent led to aldehyde 28 which was used immediately in the next step without purification. The Wittig olefination reaction of 28 with the ylide derived from hexyltriphenylphosphonium bromide and potassium bis(trimethylsilyl)amide worked well and produced methyl ester 29 in 65% yield from alcohol 27. As expected, the Wittig reaction produced exclusively the desired Z geometrical isomer under the experimental conditions used (low temperature, salt free). This is in full agreement with our earlier work on the (13S)-enantiomer (2a) where the Z stereochemistry of the C14=C15 double bond was unambiguously confirmed by using a combination of 1D and 2D NMR methods.⁶ Subsequently, saponification (85% yield), CDI mediated coupling with protected ethanolamide 23 (93% yield), and fluorodesilylation with TBAF (89% yield) led to target (13*R*)-Me-AEA (2b).

The chiral di-Me-AEA analogs **3a-e** were synthesized in a similar manner as depicted in Scheme 5. Thus, Wittig olefination of aldehyde **8a** with **25** followed by fluorodesilylation gave the Z alcohol **31**.⁶ The synthesis of the requisite tail modified acid **34b** was accomplished by following: a) oxidation with Dess-Martin periodinane, b) Wittig olefination, and c) methyl ester hydrolysis. Eventually, amide coupling of the acids **34a-e** with the chiral protected ethanolamine **36** produced the intermediate silylated amides **37a-e** that upon treatment with TBAF afforded the chiral di-Me-AEA analogs **3a-e**. Varying the head moieties of the (13*S*)-Me-substituted arachidonoyl skeleton begins with the free acid

34a coupling to the amine derivatives to give the desired amide analogs 4a-e (Scheme 6). Again, the

Page 9 of 62

CDI activation procedure worked well and produced these analogs in excellent yields (85-92%). Modifications at the tail aimed at incorporating azido and isothiocyanato functionalities are shown in Scheme 6. The requisite tail fragment **40** was synthesized in two steps from commercially available 6-bromo-hexan-1-ol (**38**) by using TBDPS protection and phosphonium salt formation reactions. Starting from alcohol **31** the Dess-Martin periodinane oxidation-Wittig olefination led to the intermediate methyl ester **41** in 64% overall yield. The terminal hydroxy group was then deprotected using TBAF to give **42** in 86% yield. At this point we had established a path to synthesize the key primary alcohol **42** which allows the further functionalization of both the terminal tail carbon and the polar head group. In the current study we focused on probes incorporating azido and isothiocyanato moieties in analogs bearing the cyclopropylamido head group. Thus, heating **42** with diphenylphosphoryl azide and DBU in dry DMF gave azide **43** in 71% yield. Saponification of azide ester **43** with LiOH led to acid **44** (95% yield) which was subjected to CDI-mediated amide coupling with cyclopropyl amine to give amide **4f** (74% yield). Subsequently, the isothiocyanato probe **4g** was isolated after treatment of the azido probe **4f** with carbon disulfide in the presence of triphenylphosphine (96% yield).

Biochemical characterization

The synthesized chiral AEA analogs were evaluated in four steps to assess their *in vitro* binding affinities, functional properties and stability for FAAH and COX-2, as follows: **1**) all analogs were assessed for affinity binding to rCB1, mCB2 and hCB2; **2**) the most promising compounds from each series were further evaluated in the adenylyl cyclase (cAMP) assay as a measure of their functional *in vitro* potency and efficacy at the CB1 receptors; **3**) all analogs were evaluated preliminarily for their stability towards FAAH by comparing the Ki values from the rCB1 binding assays in the presence and absence of the FAAH inhibitor phenylmethanesulfonylfluoride (PMSF) as we have carried out in the

past (detailed below).^{6, 24-25} This screening process served as a guide to select key AEA probes for further studies where their stabilities for expressed human and rat FAAH were assessed precisely using LC-MS/MS; **4**) representative analogs were tested for their stability towards COX-2. The discussion of the biochemical characterization follows.

a) In vitro biological activity

All AEA analogs (series **2**, **3**, and **4**) were assessed for affinity binding to rCB1, mCB2 and hCB2 receptors. Competition binding experiments using [³H]CP-55,940 as the radioligand were performed in rat brain or HEK293 cell membrane preparations. As we detailed elsewhere,⁶ amidase activity is present in rCB1 receptor preparations. Thus, binding experiments were carried out with and without pretreatment of the rCB1 membranes with phenylmethanesulfonyl fluoride (PMSF), a common protease inhibitor. CB2 affinity was measured by using receptor preparations where FAAH activity is absent.⁶ The choice of the widely used radioligand [³H]CP-55,940 as a competing ligand for the binding assays was based on considerations discussed in our earlier publications.^{6, 15} Moreover, as we detailed in earlier studies, the CB2 receptor shows less homology (~82%) between species than does CB1 (~97-99%), and this may result in species-related differences in affinity. Therefore, the AEA analogs were tested on both, mouse and human CB2.²⁶ Functional characterization of key AEA analogs possessing the highest affinities for the rCB1 receptor was performed by measuring changes in the forskolin-stimulated cAMP as we reported earlier.²⁷⁻²⁸

An examination of the binding affinity data of the chiral Me-arachidonoyl ethanolamides (chiral-Me-AEAs, **2**, Table 1) shows that presence of a chiral methyl group at the tetraolefinic chain (TC) has a striking effect on the binding affinity and selectivity of the analogs for CB1 and CB2. Thus, addition of a (13*S*)-methyl group, compound **2a**, results in a remarkable increase in the affinity of the analog for

Page 11 of 62

Journal of Medicinal Chemistry

the CB1 receptor when compared to endogenous ligand AEA. However, the (13R)-enantiomer **2b** is inactive at both CB1 and CB2 receptors. In contrast, both the (10S) and the (10R) stereochemistry is inactive at CB1 and CB2 as seen by comparing the binding affinities of the enantiomers **2c** and **2d** (Table 1). The effect of the chiral methyl group at C7 on the binding affinity of the compounds is more complex. Thus, the (7R)-enantiomer **2e** is a high affinity CB1/CB2 ligand while the (7S)-enantiomer **2f** has low affinity for both the CB1 and CB2 receptors. Cyclase data (Table 2) confirmed the effect of the stereochemistry at C7 and C13 on the bioactivity of these analogs and showed that the AEA analogs **2a** and **2e** behave as potent CB1 agonists.

Binding affinities and cyclase data for the chiral-di-Me-AEA analogs **3** are summarized in Tables 3 and **4**. Our data show that addition of a second chiral methyl group at C1' of the enantiomers **2a** and **2b** lead to diastereomeric counterparts **3a** and **3cb**, respectively, with similar SAR trends (Table 3). Thus, analog **3a** with the 13*S* stereochemistry is a high affinity ligand for rCB1 while again, the 13*R* stereochemistry is not recognized by either the CB1 or the CB2 receptors (analog **3c**). Comparisons of the binding affinities of the chiral analogs **2a** and **3a** with their achiral congeners **AEA** and **AM356**, respectively (Tables 1 and 3), confirm the superior cannabinergic activity of the chiral 13*S*-Me-AA chain versus the non-chiral AA-chain. As seen in analog **3b**, transformation of the linear *n*-pentyl tail of the 13*S*,1'*R*-di-Me-AEA **3a** to the longer and bulkier phenoxypropyl group results in a reduction of the affinity of the analog for the CB receptors which is more accentuated in CB1. Incorporation of a second chiral methyl group at the C1' of the C7-chiral-Me-AEA analogs **2e** and **2f** leads to diastereomers **3d** and **3e** (Table 3), respectively, that are both high affinity ligands for CB1 and CB2 receptors. This suggests that the C7 position is more tolerant to the structural changes when compared to C13. Our functional characterization study found that the key chiral-di-Me-AEA analogs **3a**, **3d** and **3e** potently

decrease the levels of cAMP, indicating that within this signaling mechanism these compounds behave as potent agonists at CB1 (Table 4).

The Ki values for the (13S)-Me-arachidonoyl amides 4 are presented in Table 5 and the functional potencies of representative analogs in Table 6. We observe that the cyclopropyl (4a), 2'-chloroethyl (4d) and propargyl (4e) analogs have the highest binding affinities for CB1, approximately 17-70-fold higher than the endogenous AEA while key representative analogs (4a, 4b, 4d and 4f) behave as potent agonists for CB1 in the cAMP assay. A cursory examination of the binding affinities of the analogs 4a, 4b and 4c for CB1 suggest that increasing the size of the cycloalkylamino head group from a cyclopropyl to a bulkier cyclobutyl or cyclopentyl ring leads to a progressive reduction of the affinity for CB1. Interestingly, analogs 4a, 4b, 4d and 4e exhibit substantial binding affinity for the CB2 receptor with preference for the hCB2 versus the mCB2. To this end the cyclobutyl analog 4b has a 3-13-fold preference for hCB2 over rCB1 and mCB2. Incorporation of a polar azido or isothiocyanato group at the terminal carbon atom (C20) of the chiral cyclopropylamido analog 4a leads to head/tail hybrid analogs 4f and 4g that bind equally well to both rCB1, mCB2 and hCB2 receptors. This supports a more general observation through this SAR study, that combinations of the TC's chiral features with appropriate head- and/or tail-groups can generate AEA analogs with high affinity for CB2, a finding that has not been reported for AEA analogs. Additionally, analogs 4f and 4g carrying the photoactivatable azido and the electrophilic isothiocyanato groups were tested for their ability to irreversibly label the rCB1 and the hCB2 receptors by following established procedures developed in our laboratory.^{20, 29-30} Our studies indicated that both 4f and 4g are not covalent binders at CB1 and CB2. Overall, our biochemical evaluation led to the discovery of novel chiral AEA ligands with distinct biological profiles including CB1 selective (e. g., 2a and 3a), and dual CB1/CB2 probes (e.g., 2e, 3d, 4a, 4b, 4f and 4g). Key representative analogs behave as potent CB1 agonists.

b) Metabolic stability for FAAH and COX-2

Metabolic stability for AEA and representative chiral-Me-AEAs, chiral-di-Me-AEAs and (13S)-Me-AAs are summarized in Table 7. As we reported in earlier studies, comparisons of a compound's Ki values for rCB1 obtained with and without the presence of PMSF (see Tables 1, 2 and 4), can serve as a preliminary assessment of the stability of that compound towards FAAH hydrolysis. Thus, the rCB1 binding assays were performed twice for each AEA analog, once after treatment of the membranes with PMSF to protect against FAAH hydrolysis, and a second time without pretreating the membranes with PMSF where enzymatic activity is not blocked.²⁴⁻²⁵ Very little or no effect of PMSF on CB1 receptor binding affinity (Ki) is considered as an indication of enzymatic stability (see Table 7).²⁴⁻²⁵ This preliminary screening of AEA and its analogs served as a guide to select AEA probes for further studies where their stabilities for expressed human FAAH were assessed quantitatively using LC-MS/MS methods. For species comparisons (rat versus human) AEA and one of the chiral analogs (3d) were tested in both rat and human FAAH preparations. Overall, our studies have identified AEA probes with excellent stability for the human FAAH enzyme including all chiral-di-Me-AEA ligands (3) and the (13S)-Me-AA analogs 4b, 4c, 4d, 4f, and 4g. In addition, our data indicate that AEA is recognized equally well from both the rat and human clone while **3d** maintains its excellent FAAH stability for both species. As in earlier work,³¹ we have used a polarographic assay that measures oxygen consumption to investigate the endogenous AEA, arachidonic acid, and key analogs as substrates for mCOX-2 activity. Data are presented in Figure 4. In agreement with our rational design our studies indicate that incorporation of a chiral methyl group at positions C7 and C13 of the endogenous prototype enhances the stability of the TCs towards COX-2. A finding which is reported here for first time for AEA ligands. Our key analog **3a** [(13S, 1'R)-di-Me-AEA] was further tested for stability in

both human MGL and human ABHD6 using HPLC methods (see experimental section) and found to be stable for 30 min.

Molecular modeling

 In an effort to understand the large binding affinity difference between the two AEA analogs, **3a** and **3c** we performed docking studies in the CB₁R* model as we reported in earlier work.²⁰ Methods are detailed under Supporting Information. As illustrated in Figure 5A, our docking studies suggest that **3a** sits high in the receptor in the TMH2-3-6-7 region and establishes its primary interaction with K3.28. The (13*S*)-methyl group of **3a** defines its particular binding affinity and makes it enantioselective at CB₁. This stereocenter adds conformational restriction in this region of the molecule directing the methyl group into a hydrophobic pocket defined by K3.28, L3.29 and above V3.32, establishing strong Van der Waals interactions. The alkyl tail is directed upward in the binding site, establishing hydrophobic interactions with T3.33 and Y5.39. Attempts were made to dock **3c** in the same binding pocket region as the **3a** binding site. However, the (13*R*)-methyl group of **3c** forces the ligand towards TMH6 where it has steric overlap with L6.51 (Figure 5B). This overlap precludes **3c** binding at CB1. Our docking studies provide a rational structural basis of the CB₁ enantioselectivity of **3a** over **3c**. Although the enantioselective actions of THC and related exogenous cannabinoids on CB1 receptor are well established, this phenomenon is observed here for first time with the endocannabinoid scaffold.

In vivo behavioral characterization

a) Results. AMG315 produced anti-allodynic effect in CFA-induced inflammatory pain which was CB1 receptor dependent. We first examined the anti-allodynic efficacy of AEA (20 mg/kg i.p.) in CFA-induced inflammatory pain. Intraplantar injection of CFA significantly reduced the mechanical paw

withdrawal threshold on the ipsilateral side (injected paw) ($F_{1, 10} = 268.2, p < 0.001$) to similar extent in both groups ($F_{1, 10} = 0.120$, p = 0.736) before pharmacological treatments (Figure 6A), no group differences in inflammatory nociception was observed prior to pharmacological manipulations ($F_{1,10}$ = 0.016, p = 0.903). During the maintenance phase of CFA-induced inflammatory pain, mechanical thresholds changed over time (F $_{3, 30} = 7.161$, p < 0.001) but did not differ between groups (F $_{1, 10} =$ 1.717, p = 0.219), although the interaction (F_{3, 30} = 3.563, p = 0.026) between groups and time were significant (Figure 6A). Bonferroni post hoc tests revealed that AEA produced only a transient antiallodynic effect at 10 minutes post injection (p = 0.014) and anti-allodynic efficacy was no longer present at 30 minutes post injection (Figure 6A). This transient anti-allodynic effect of AEA is consistent with rapid degradation of this fatty-acid amide by fatty acid amide hydrolase (FAAH). We then compared the anti-allodynic effects of compounds likely to exhibit improved metabolic stability compared to AEA. We compared the antiallodynic efficacy of AMG315 (5 mg/kg i.p.) and AM356 (20 mg/kg i.p.) in the same pain model (Figure 6C). During the maintenance phase of CFAinduced inflammatory pain, AMG315 (5 mg/kg, i.p.) and AM356 (20 mg/kg, i.p.) increased mechanical paw withdrawal thresholds ($F_{2,15} = 20.82$, p < 0.001) in a treatment-dependent manner ($F_{6,45} = 4.706$, p = 0.001) and the mechanical paw withdrawal threshold changed over time ($F_{3, 45} = 16.1, p < 0.001$) (Figure 6C). Bonferroni post hoc tests revealed that both AMG315 (5 mg/kg) and AM356 (20 mg/kg) significantly increased mechanical paw withdrawal threshold at 10 minutes post injection compared with the vehicle group (p < 0.001) (Figure 6C). Moreover, mechanical paw withdrawal threshold was higher in CFA-injected mice that received AMG315 (5 mg/kg i.p.) compared to AM356 (20 mg/kg) at 10 minutes post injection (p = 0.021), consistent with improved efficacy of AM315 compared to

AM356. In contrast to AEA, both AMG315 and AM356 displayed longer duration of action which lasted up to 30 minutes (Figure 6C). In addition, only AM356 (20 mg/kg) increased mechanical paw

withdrawal thresholds in the CFA-injected paw compared to mice receiving vehicle at 60 minutes post injection (p = 0.014). Mechanical paw withdrawal threshold in the CFA-injected paw were similar in mice receiving AM315 and AM356 at this time point (p = 1).

To determine if anti-allodynic effects of AMG315 were mediated by CB1 receptors, the antiallodynic effect of AMG315 (5 mg/kg, i.p.) was compared in WT and CB1 KO mice (Figure 6E). Post-injection mechanical paw withdrawal thresholds differed between groups and across post-injections times and the interaction between group and time was significant ($F_{2,15} = 17.545$, p < 0.001 [group]; $F_{3,45} = 9.67$, p < 0.001 [time]; $F_{6, 45} = 2.961$, p = 0.016 [interaction]) (Figure 6E). WT mice receiving AMG315 showed elevated mechanical paw withdrawal thresholds compared to the vehicle group at 10 and 30 minutes post injection (p < 0.001). By contrast, mechanical paw withdrawal thresholds in CB1 KO mice receiving AM315 did not differ from that of the vehicle group at any time points tested (Figure 6E). The CFA injection induced a slight increase in the mechanical paw withdrawal threshold on the contralateral side (un-injected paw), an expected consequence of uneven weight bearing of the hind paws after CFA injection (Figure 6, D, F). However, pharmacological manipulations did not alter the mechanical paw withdrawal threshold of the contralateral paw during the maintenance phase of CFAinduced inflammatory pain at any timepoint (Figure 6B: $F_{3,30} = 1.016$, p = 0.400 [time]; $F_{1,10} = 0.024$, p = 0.880 [group]; $F_{3,30} = 1.134$, p = 0.351 [interaction]; Figure 6D: $F_{3,45} = 0.515$, p = 0.674 [time]; F $_{2,15} = 0.616, p = 0.553$ [group]; $F_{6,45} = 0.189, p = 0.978$ [interaction]; Figure 6F: $F_{3,45} = 0.328, p = 0.328$ 0.850 [time]; $F_{2,15} = 0.835$, p = 0.453 [group]; $F_{6,45} = 0.499$, p = 0.806 [interaction]).

b) Discussion. The metabolically stable anandamide analog AMG315 (5 mg/kg i.p.) suppressed CFAinduced mechanical allodynia through a CB1 mechanism. Antinociceptive effects of AMG315 were restricted to the CFA-injected (ipsilateral) paw and were absent in the noninjected (contralateral) paw. The duration of action of AMG315 and AM356 outlasted that of AEA. AMG315 also produced greater

Journal of Medicinal Chemistry

anti-allodynic efficacy than AM356 at 10 minutes post injection, but did not exhibit a longer duration of action than AM356, suggesting possible superiority of AMG315 relative to AM356. By sparing metabolic degradation by both FAAH and COX, the magnitude of anti-allodynic efficacy may be increased preferentially (as opposed to duration of action). The anti-allodynic efficacy of AMG315 observed in WT mice was largely absent in CB1KO mice, suggesting a CB1 mechanism of action. The same vehicle alone did not alter the responding in CB1 KO mice in our previous work.³²

CONCLUSIONS

We report the first AEA probe, namely, (13*S*, 1'*R*)-dimethyl-anandamide [(13*S*, 1'*R*)-di-Me-AEA, **3a**] possessing high affinity and potency for the cannabinoid CB1 receptor coupled with excellent biochemical stability for FAAH, MGL, ABHD6 and COX-2. When tested in vivo using the CFA-induced inflammatory pain model **3a** behaved as a more potent analgesic when compared to endogenous AEA or its hydrolytically stable analog AM356.

This was the result of a careful SAR study that led to novel AEA ligands with modified tetraolefinic chains and unique pharmacological profiles including CB1 selective (e. g., **2a** and **3a**), and dual CB1/CB2 probes (e.g., **2e**, **3d**, **4a**, **4b**, **4f** and **4g**). Our approach for developing the novel metabolically stable AEA analogs was based on introducing chirality with conformational restriction in the tetraolefinic chain of the prototype. Key representative analogs behave as potent CB1 agonists and have enhanced stability for COX-2 while the head group analogs are endowed with stability towards FAAH. Unlike AEA the chiral ligands reported here do not generate arachidonic acid which exhibits non-CB-mediated biological actions as well as *in vitro* and *in vivo* toxicity. As such, these ligands will be valuable experimental tools currently lacking for future *in vitro*, *in vivo*, and theoretical studies aimed at exploring the (patho)physiological roles of the endocannabinoid system.

EXPERIMENTAL SECTION

Materials: All reagents and solvents were purchased from Aldrich Chemical Company, unless otherwise specified, and used without further purification. All anhydrous reactions were performed under a static argon or nitrogen atmosphere in flame-dried glassware using scrupulously dry solvents. Flash column chromatography employed silica gel 60 (230-400 mesh). All compounds were demonstrated to be homogeneous by analytical TLC on pre-coated silica gel TLC plates (Merck, 60 F_{245} on glass, layer thickness 250 μ m), and chromatograms were visualized by phosphomolybdic acid staining. Melting points were determined on a micro-melting point apparatus and are uncorrected. NMR spectra were recorded in CDCl₃, unless otherwise stated, on Varian 600 (¹H at 600 MHz, ¹³C at 150 MHz), Varian 500 (¹H at 500 MHz), Varian 300 (¹³C at 75 MHz), and Bruker 400 (¹H at 400 MHz, ¹³C at 100 MHz) NMR spectrometers and chemical shifts are reported in units of δ relative to internal TMS. Multiplicities are indicated as br (broadened), s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and coupling constants (J) are reported in hertz (Hz). Low and high-resolution mass spectra were performed in School of Chemical Sciences, University of Illinois at Urbana-Champaign. Mass spectral data are reported in the form of m/z (intensity relative to base = 100). Purities of the tested compounds were determined by LC/MS analysis using a Waters MicroMass ZQ system (electrospray ionization (ESI) with Waters-2525 binary gradient module coupled to a photodiode array detector (Waters-2996) and ELS detector (Waters-2424) using a XTerra MS C18 (5 μ m, 4.6 mm × 50 mm column and acetonitrile/water) and were > 95 %.

(13*R*,5*Z*,8*Z*,11*Z*,14*Z*)-*N*-(2-Hydroxyethyl)-13-methyleicosa-5,8,11,14-tetraenamide (2b). To a solution of **30** (25 mg, 0.04 mmol) in dry THF (0.8 mL) at 0 °C, under an argon atmosphere, was added tetra-*n*-butylammonium fluoride (TBAF, 0.05 mL, 0.05 mmol, 1M solution in THF) dropwise. The

reaction mixture was stirred for 10 min at 0 °C and for 1.5 hours at room temperature, and then it was quenched with saturated aqueous NH₄Cl at 0 °C and extracted with EtOAc. The combined organic extracts were washed with brine, dried over MgSO4 and the solvent was evaporated under reduced pressure at 35-37 °C. The residue was purified by flash column chromatography on silica gel (40 % EtOAc/hexane) to give **2b** (13 mg, 89 % yield) as a colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 0.89 (t, J = 6.9 Hz, 3H, 20-H), 1.02 (d, J = 7.2 Hz, 3H, >CH-CH₃), 1.24-1.33 (m, 4H, 18-H, 19-H), 1.35 (sextet, J = 7.2 Hz, 2H, 17-H), 1.73 (quintet, J = 7.2 Hz, 2H, 3-H), 2.06 (nonet, J = 6.3 Hz, 2H, 16-H), 2.12 (dt, J = 7.2 Hz, J = 7.2 Hz, 2H, 4-H), 2.22 (t, J = 7.6 Hz, 2H, 2-H), 2.52 (br s, 1H, -OH), 2.76-2.84 (ddd and t, overlapping, 3H, 10-H and 7-H, especially 2.81, t, J = 6.0 Hz, 2H, 7-H), 2.87 (ddd, J = 15.0Hz, J = 7.5 Hz, J = 6.3 Hz, 1H, 10-H), 3.42 (dt, J = 5.2 Hz, J = 5.2 Hz, 2H, -CH₂-N<), 3.46 (sextet, J = 5.2 Hz, 2H, -CH₂-N<), 3.46 (sextet 7.5 Hz, 1H, 13-H), 3.73 (t, J = 5.2 Hz, 2H, -CH₂O-), 5.20-5.31 (m, 4H, 11-H, 12-H, 14-H, 15-H), 5.44-5.32 (m, 4H, 5-H, 6-H, 8-H, 9-H), 5.88 (br s, 1H, >NH); ¹³C NMR (150 MHz, CDCl₃) δ 174.16 (>C=O), 135.10 (C-12), 134.12 (C-14), 129.02 (C-8), 128.84 (C-5), 128.43 (C-6), 128.26 (C-15), 128.10 (C-9), 125.61 (C-11), 62.70 (-CH2-OH), 42.48 (NH-CH2), 35.92 (C-2), 31.57 (C-18), 30.50 (C-13), 29.46 (C-17), 27.51 (C-16), 26.61 (C-4), 25.84 (C-10), 25.61 (C-7), 25.44 (C-3), 22.59 (C-19), 22.04 (C-13-CH₃), 14.09 (C-20). Mass spectrum (ESI) m/z (relative intensity) 384 (M⁺ + Na), 362 (M⁺ + H, 100), 301 (7). Exact mass (ESI) calculated for $C_{23}H_{40}NO_2$ (M⁺ + H), 362.3059; found, 362.3047. LC/MS analysis (Waters MicroMass ZQ system) showed purity 98% and retention time 5.8 min for the title compound.

(7*R*,5*Z*,8*Z*,11*Z*,14*Z*)-*N*-(2-Hydroxyethyl)-7-methyleicosa-5,8,11,14-tetraenamide (2e). The synthesis was carried out as described for 2b bellow, using 24a (30 mg, 0.05 mmol) and TBAF (0.07 mL, 1M solution in THF) in dry THF (3 mL). The reaction was completed in 1 hour and the crude oil

obtained after work up was purified by flash column chromatography on silica gel (15% EtOAc/hexane) to give **2e** (15 mg, 85 % yield) as a colorless oil. IR (neat): 3303, 3012, 2927, 2857, 1646 (C=O), 1543, 1275, 1261, 1066 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.89 (t, *J* = 6.8 Hz, 3H, 20-H), 1.02 (d, *J* = 6.8 Hz, 3H, >CH-CH₃), 1.23 – 1.41 (m, 6H, 17-H, 18-H, 19-H), 1.73 (quintet, *J* = 7.5 Hz, 2H, 3-H), 2.06 (dt, *J* = 7.3 Hz, *J* = 7.3 Hz, 2H, 16-H), 2.09 – 2.18 (m, 2H, 4-H), 2.21 (t, *J* = 7.5 Hz, 2H, 2-H), 2.73 – 2.94 (m, 4H, 10-H, 13-H), 3.38 – 3.50 (sextet and dt overlapping, 3H, 7-H, -CH₂-NH-), 3.72 (t, *J* = 5.0 Hz, 2H, -CH₂OH), 5.20 – 5.46 (m, 8H, 5-H, 6-H, 8-H, 9-H, 11-H, 12-H, 14-H, 15-H), 5.87 (br s, 1H, -NH-). ¹³C NMR (100 MHz, CDCl₃) δ 174.1 (C=O), 135.3 (C=C), 134.7 (C=C), 130.5 (C=C), 128.6 (C=C), 128.0 (C=C), 127.5 (C=C), 126.8 (C=C), 125.9 (C=C), 62.7 (CH₂OH), 42.5 (-NHCH₂-), 36.0, 31.5, 30.5, 29.3, 27.2, 26.9, 25.8, 25.6, 25.5, 22.5, 22.0, 14.0. Mass spectrum (ESI) m/z (relative intensity) 362 (M⁺ + H, 100). Exact mass (ESI) calculated for C₂₃H₄₀NO₂ (M⁺ + H), 362.3059; found, 362.3073. LC/MS analysis (Waters MicroMass ZQ system) showed purity 99% and retention time 5.4 min for the title compound.

(75,5Z,8Z,11Z,14Z)-*N*-(2-Hydroxyethyl)-7-methyleicosa-5,8,11,14-tetraenamide (2f). The synthesis was carried out as described for 2b bellow, using 24b (30 mg, 0.05 mmol) and TBAF (0.07 mL, 1M solution in THF) in dry THF (3 mL). The reaction was completed in 1 hour and the crude oil obtained after work up was purified by flash column chromatography on silica gel (15 % EtOAc/hexane) to give 2f (16 mg, 88 % yield) as a colorless oil. The IR, ¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectrum was identical to that of the enantiomer 2e. Mass spectrum (ESI) m/z (relative intensity) 384 (M⁺ + Na, 18), 362 (M⁺ + H, 100), 301 (7). Exact mass (ESI) calculated for C₂₃H₄₀NO₂ (M⁺ + H), 362.3059; found, 362.3062. LC/MS analysis (Waters MicroMass ZQ system) showed purity 99 % and retention time 5.4 min for the title compound.

(13*S*,5*Z*,8*Z*,11*Z*,14*Z*)-*N*-((*R*)-1-Hydroxypropan-2-yl)-13-methyleicosa-5,8,11,14-tetraenamide

(3a). To a solution of 37a (25 mg, 0.04 mmol) in dry THF (0.8 mL) at 0 °C under an argon atmosphere, was added TBAF (0.05 mL, 1M solution in THF) dropwise. The reaction mixture was stirred for 10 min at 0 °C and for 1.5 hours at room temperature, and then it was guenched with saturated aqueous NH4Cl at 0 °C and extracted with EtOAc. The combined organic extracts were washed with brine, dried over MgSO₄ and the solvent was evaporated under reduced pressure at 35-37 °C. The residue was purified by flash column chromatography on silica gel (40% EtOAc/hexane) to give **3a** (13 mg, 87 % yield) as a colorless oil. IR (neat): 3300, 3019, 2926, 2861, 1644 (C=O), 1540, 1273, 1262, 1069 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 0.89 (t, J = 6.7 Hz, 3H, 20-H), 1.02 (d, J = 6.6 Hz, 3H, =CH-CH(CH₃)-), 1.17 (d, J = 6.6 Hz, 3H, >N-CH(CH₃)-), 1.24 – 1.32 (m, 4H, 18-H, 19-H), 1.35 (sextet, J = 7.2 Hz, 2H, 17-H), 1.72 (quintet, J = 7.2 Hz, 2H, 3-H), 2.06 (nonet, J = 6.2 Hz, 2H, 16-H), 2.12 (dt, J = 7.2 Hz, J = 7.2 Hz, 2H, 4-H), 2.20 (t, J = 7.8 Hz, 2H, 2-H), 2.76 – 2.84 (ddd and t, overlapping, 3H, 10-H and 7-H, especially 2.81, t, J = 6.0 Hz, 2H, 7-H), 2.87 (ddd, J = 15.0 Hz, J = 7.5 Hz, J = 6.2 Hz, 1H, 10-H), 3.46 (sextet, J = 7.5 Hz, 1H, 13-H), 3.53 (dd, J = 10.8 Hz, J = 6.0 Hz, 1H, -CH₂-O-), 3.67 (dd, J = 10.8Hz, J = 3.6 Hz, 1H, -CH₂-O-), 3.68 (br s, 1H, -OH), 4.08 (m, 1H, >N-CH(CH₃)-), 5.20 - 5.30 (m, 4H, 11-H, 12-H, 14-H, 15-H), 5.32 – 5.44 (m, 4H, 5-H, 6-H, 8-H, 9-H), 5.60 (br s, 1H, >NH). ¹³C NMR (75) MHz, CDCl₃) δ 173.7 (>C=O), 135.1 (C-12), 134.1 (C-14), 129.0 (C-8), 128.8 (C-5), 128.4 (C-6), 128.2 (C-15), 128.1 (C-9), 125.6 (C-11), 67.4 (-CH₂-OH), 47.8 (-NH-CH<), 36.1 (C-2), 31.6 (C-18), 30.5 (C-13), 29.5 (C-17), 27.5 (C-16), 26.6 (C-4), 25.8 (C-10), 25.6 (C-7), 25.5 (C-3), 22.6 (C-19), 22.0 (C-13-CH₃), 17.1 (-NH-CH(CH₃)-), 14.1 (C-20); Mass spectrum (EI) m/z (relative intensity) 376 (M+H¹⁺, 1), 375 (M⁺, 2), 357 (5), 342 (7), 232 (8), 192 (12), 152 (15), 139 (22), 112 (39), 99 (100); Exact mass (EI) calculated for $C_{24}H_{42}NO_2$ (M+H]⁺), 376.3216; found, 376.3213; Mass spectrum (ESI)

m/z (relative intensity) 376 (M+H 1^+ , 100), 339 (15), 301 (11), 269 (13); Exact mass (ESI) calculated for C₂₄H₄₂NO₂ (M+H 1^+), 376.3216; found, 376.3210. LC/MS analysis (Waters MicroMass ZQ system) showed purity 98% and retention time 5.5 min for the title compound.

(13S,5Z,8Z,11Z,14Z)-N-((R)-1-Hydroxypropan-2-yl)-13-methyl-18-phenoxyoctadeca-5,8,11,14-

tetraenamide (3b). The synthesis was carried out as described for 3a, using 37b (22 mg, 0.036 mmol) and TBAF (0.045 mL, 1M solution in THF) in dry THF (0.7 mL). The reaction was completed in 1.5 hours and the crude oil obtained after work up was purified by flash column chromatography on silica gel (57:40:3 ethyl acetate:hexane:MeOH) to give **3b** (12 mg, 85 % yield) as a colorless oil. ¹H NMR $(600 \text{ MHz}, \text{CDCl}_3) \delta 0.99 \text{ (d, } J = 7.2 \text{ Hz}, 3\text{H}, =\text{CH-CH}(\text{CH}_3)\text{-}), 1.15 \text{ (d, } J = 6.6 \text{ Hz}, 3\text{H}, >\text{N-CH}(\text{CH}_3)\text{-}),$ 1.71 (quintet, J = 7.2 Hz, 2H, 3-H), 1.85 (m, 2H, 17-H), 2.10 (dt, J = 6.6 Hz, J = 6.6 Hz, 2H, 4-H), 2.17 (t, J = 7.2 Hz, 2H, 2-H), 2.20 - 2.26 (m, 1H, 16-H), 2.26 - 2.34 (m, 1H, 16-H), 2.75 - 2.85 (ddd and t, 1)overlapping, 3H, 10-H and 7-H, especially 2.80, t, J = 6.0 Hz, 2H, 7-H), 2.87 (ddd, J = 15.6 Hz, J = 7.5Hz, J = 6.5 Hz, 1H, 10-H), 3.49 (ddq as sextet, J = 7.2 Hz, 1H, 13-H), 3.51 (dd, J = 10.8 Hz, J = 6.3Hz, 1H, $-CH_2$ -OH), 3.65 (dd, J = 10.8 Hz, J = 3.3 Hz, 1H, $-CH_2$ -OH), 3.96 (t, J = 6.6 Hz, 2H, 18-H), 4.06 (m, 1H, >N-CH(CH₃)-), 5.20 – 5.42 (m, 8H, 5-H, 6-H, 8-H, 9-H, 11-H, 12-H, 14-H, 15-H), 5.57 (br s, 1H, >NH), 6.89 (d, J = 7.4 Hz, 2H, 2-H, 6-H, -OPh), 6.93 (t, J = 7.4 Hz, 1H, 4-H, -OPh), 7.27 (t, J = 7.4 Hz, 2H, 3-H, 5-H, -OPh). ¹³C NMR (75 MHz, CDCl₃) δ 173.7 (>C=O), 159.0 (C-1', Ar), 135.3, 134.8, 129.4 (C-3', C-5', Ar), 129.1, 128.8, 128.3, 128.1, 126.8, 125.8, 120.5 (C-4', Ar), 114.5 (C-2', C-6', Ar), 67.5 (-CH₂O-), 67.0 (-CH₂O-), 47.8 (-NH-CH<), 36.0 (C-2), 30.5, 29.2, 26.6, 25.8, 25.6, 25.4, 24.0, 21.9, 17.0 (-NH-CH(CH_3)-); Mass spectrum (EI) m/z (relative intensity) 439 (M⁺, 4), 421 (15), 406 (8), 328 (9), 300 (8), 232 (13), 192 (14), 152 (19), 139 (35), 112 (37), 99 (100); Exact mass (EI)

calculated for $C_{28}H_{41}NO_3$, 439.3086; found, 439.3083. LC/MS analysis (Waters MicroMass ZQ system) showed purity 97% and retention time 5.2 min for the title compound.

(13R,5Z,8Z,11Z,14Z)-N-((R)-1-Hydroxypropan-2-yl)-13-methyleicosa-5,8,11,14-tetraenamide

(3c). The synthesis was carried out as described for 3a, using 37c (14 mg, 0.023 mmol) and TBAF (0.03 mL, 0.03 mmol, 1 M solution in THF) in dry THF (0.5 mL). The reaction was completed in 1.5 hours and the crude product obtained after work up was purified by flash column chromatography on silica gel (57:40:3 ethyl acetate:hexane:MeOH) to give **3c** (7 mg, 80 % yield) as a colorless oil. IR (neat): 3304, 3013, 2927, 2857, 1653 (C=O), 1543, 1275, 1261, 1066 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 0.89 (t, J = 6.7 Hz, 3H, 20-H), 1.02 (d, J = 6.6 Hz, 3H, =CH-CH(CH₃)-), 1.17 (d, J = 6.6 Hz, 3H, >N-CH(CH₃)-), 1.24 - 1.32 (m, 4H, 18-H, 19-H), 1.35 (sextet, J = 7.2 Hz, 2H, 17-H), 1.72 (quintet, J = 7.2 Hz, 2H, 3-H), 2.06 (nonet, J = 6.2 Hz, 2H, 16-H), 2.12 (dt, J = 7.2 Hz, J = 7.2 Hz, 2H, 4-H), 2.20 (t, J = 7.8 Hz, 2H, 2-H), 2.79 – 2.85 (ddd and t, overlapping, 3H, 10-H and 7-H, especially 2.81, t, J = 6.0 Hz, 2H, 7-H), 2.87 (ddd, J = 15.0 Hz, J = 7.5 Hz, J = 6.2 Hz, 1H, 10-H), 3.46 (sextet, J = 7.5Hz, 1H, 13-H), 3.53 (dd, J = 10.8 Hz, J = 6.0 Hz, 1H, -CH₂-O-), 3.67 (dd, J = 10.8 Hz, J = 3.6 Hz, 1H, -CH₂-O-), 3.68 (br s, 1H, -OH), 4.08 (m, 1H, >N-CH(CH₃)-), 5.20 – 5.31 (m, 4H, 11-H, 12-H, 14-H, 15-H), 5.32 – 5.44 (m, 4H, 5-H, 6-H, 8-H, 9-H), 5.55 (br s, 1H, >NH). ¹³C NMR (75 MHz, CDCl₃) δ 173.7 (>C=O), 135.1 (C-12), 134.1 (C-14), 129.0 (C-8), 128.8 (C-5), 128.4 (C-6), 128.2 (C-15), 128.1 (C-9), 125.6 (C-11), 67.4 (-CH₂-OH), 47.8 (-NH-CH<), 36.1 (C-2), 31.6 (C-18), 30.5 (C-13), 29.4 (C-17), 27.5 (C-16), 26.6 (C-4), 25.8 (C-10), 25.6 (C-7), 25.5 (C-3), 22.6 (C-19), 22.0 (C-13-CH₃), 17.1 (-NH-CH(CH₃)-), 14.1 (C-20). MS (EI): *m*/*z* (%): 375 (M⁺, 1), 374 (2), 312 (11), 284 (17), 257 (23), 244 (30), 171 (41), 57 (100); Exact mass (EI) calculated for C₂₄H₄₁NO₂, 375.3137; found, 375.3128; MS (ESI): m/z (%): 376 (M+H]⁺, 52), 339 (84), 269 (100); Exact mass (ESI) calculated for C₂₄H₄₂NO₂

(M+H1⁺), 376.3216; found, 376.3203. LC/MS analysis (Waters MicroMass ZQ system) showed purity 98% and retention time 5.5 min for the title compound.

(7R,5Z,8Z,11Z,14Z)-N-((R)-1-Hydroxypropan-2-yl)-7-methyleicosa-5,8,11,14-tetraenamide (3d). The synthesis was carried out as described for 3a, using 37d (20 mg, 0.032 mmol) and TBAF (0.03 mL, 0.03 mmol, 1 M solution in THF) in dry THF (0.5 mL). The reaction was completed in 1.5 hours and the crude product obtained after work up was purified by flash column chromatography on silica gel (57:40:3 ethyl acetate:hexane:MeOH) to give **3d** (10 mg, 85 % yield) as a colorless oil. IR (neat): 3302, 3011, 2927, 2857, 1647 (C=O), 1542, 1270, 1261, 1061 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.89 (t, J = 6.9 Hz, 3H, 20-H), 1.02 (d, J = 6.7 Hz, 3H, =CH-CH(CH₃)-), 1.17 (d, J = 6.7 Hz, 3H, >CH- CH_3), 1.23 – 1.42 (m, 6H, 17-H, 18-H, 19-H), 1.67 – 1.78 (quintet, J = 7.0 Hz, 2H, 3-H), 2.06 (dt, J =7.0 Hz, J = 7.0 Hz, 2H, 16-H), 2.09 – 2.17 (m, 2H, 4-H), 2.19 (t, J = 7.5 Hz, 2H, 2-H), 2.75 – 2.91 (m, 4H, 10-H, 13-H), 3.44 (sextet, J = 7.0 Hz, 1H, 7-H), 3.53 (m as qtd, J = 10.8 Hz, J = 3.7 Hz, 1H, -CH₂OH), 3.66 (m as br d, J = 10.8 Hz, 1H, -CH₂OH), 4.07 (m, 1H, >CH(CH₃)), 5.20 - 5.45 (m, 8H, 5-H, 6-H, 8-H, 9-H, 11-H, 12-H, 14-H, 15-H), 5.56 (br d, J = 5.3 Hz, 1H, >NH). ¹³C NMR (100 MHz, CDCl₃) § 173.6 (C=O), 135.3 (C=C), 134.7 (C=C), 130.5 (C=C), 128.6 (C=C), 128.0 (C=C), 127.5 (C=C), 126.8 (C=C), 125.9 (C=C), 67.5 (CH₂OH), 47.9 (-NHCH<), 36.1, 31.5, 30.5, 29.3, 27.2, 26.9, 25.8, 25.6, 25.5, 22.5, 22.0, 17.0, 14.0. Mass spectrum (ESI) m/z (relative intensity) 377 (M^+ + 2H, 25), 376 (M^+ + H, 100), 301 (8). Exact mass (ESI) calculated for C₂₄H₄₂NO₂ (M^+ + H), 376.3216; found, 376.3208. LC/MS analysis (Waters MicroMass ZQ system) showed purity 98% and retention time 5.5 min for the title compound.

(7S,5Z,8Z,11Z,14Z)-N-((R)-1-Hydroxypropan-2-yl)-7-methyleicosa-5,8,11,14-tetraenamide (**3e**). The synthesis was carried out as described for **3a**, using **37e** (20 mg, 0.032 mmol) and TBAF (0.03 mL, 0.03 mmol, 1 M solution in THF) in dry THF (0.5 mL). The reaction was completed in 1.5 hours and the crude product obtained after work up was purified by flash column chromatography on silica gel (57:40:3 ethyl acetate:hexane:MeOH) to give **3e** (10 mg, 81 % yield) as a colorless oil. IR (neat): 3304, 3012, 2927, 2857, 1650 (C=O), 1543, 1278, 1264, 1059 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.89 (t, J = 6.9 Hz, 3H, 20-H), 1.02 (d, J = 6.7 Hz, 3H, =CH-CH(CH₃)-), 1.17 (d, J = 6.7 Hz, 3H, >CH-CH₃), 1.23 - 1.42 (m, 6H, 17-H, 18-H, 19-H), 1.67 - 1.78 (quintet, J = 7.0 Hz, 2H, 3-H), 2.06 (dt, J = 7.0 Hz, J = 7.0 Hz, 2H, 16-H), 2.09 – 2.17 (m, 2H, 4-H), 2.19 (t, J = 7.5 Hz, 2H, 2-H), 2.75 – 2.91 (m, 4H, 10-H, 13-H), 3.44 (sextet, J = 7.0 Hz, 1H, 7-H), 3.53 (m as qtd, J = 10.8 Hz, J = 3.7 Hz, 1H, -CH₂OH), 3.66 (m as br d, J = 10.8 Hz, 1H, -CH₂OH), 4.07 (m, 1H, >CH(CH₃)), 5.20 - 5.45 (m, 8H, 5-H, 6-H, 8-H, 9-H, 11-H, 12-H, 14-H, 15-H), 5.56 (br d, J = 5.3 Hz, 1H, >NH). ¹³C NMR (100 MHz, CDCl₃) δ 173.7 (C=O), 135.4 (C=C), 134.7 (C=C), 130.6 (C=C), 128.6 (C=C), 128.0 (C=C), 127.5 (C=C), 126.8 (C=C), 125.9 (C=C), 67.5 (CH₂OH), 47.9 (NHCH), 36.2, 31.5, 30.5, 29.3, 27.2, 26.9, 25.8, 25.6, 25.6, 22.5, 22.0, 17.0, 14.0. Mass spectrum (ESI) m/z (relative intensity) 398 (M⁺ + Na, 8), 376 (M⁺ + H, 100), 301 (8). Exact mass (ESI) calculated for $C_{24}H_{42}NO_2$ (M⁺ + H), 376.3216; found, 376.3206. LC/MS analysis (Waters MicroMass ZQ system) showed purity 98% and retention time 5.5 min for the title compound.

(13S,5Z,8Z,11Z,14Z)-*N*-Cyclopropyl-13-methyleicosa-5,8,11,14-tetraenamide (4a). A solution of (13S,5Z,8Z,11Z,14Z)-13-methyleicosa-5,8,11,14-tetraenoic acid (34a, 12 mg, 0.04 mmol), and dried carbonyldiimidazole (18 mg, 0.113 mmol) in dry THF (0.63 mL) at room temperature under an argon atmosphere, was stirred for 2 hours and then a solution of cyclopropyl amine (9 mg, 0.151 mmol) in

THF (0.2 mL) was added. The reaction mixture was stirred for 1 hour and then diluted with water and ethyl acetate. The organic phase was separated, and the aqueous phase extracted with AcOEt. The combined organic layer was washed with brine, dried over MgSO₄ and concentrated under reduced pressure. Purification by flash column chromatography on silica gel (25 % acetone in hexane) gave 12 mg (91 % yield) of **4a** as a colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 0.47 (m, 2H of the cyclopropy) ring), 0.76 (m, 2H of the cyclopropyl ring), 0.89 (t, J = 6.9 Hz, 3H, 20-H), 1.02 (d, J = 6.6 Hz, 3H, >CH-CH₃), 1.24 - 1.33 (m, 4H, 18-H, 19-H), 1.35 (sextet, J = 7.2 Hz, 2H, 17-H), 1.71 (quintet, J = 7.2Hz, 2H, 3-H), 2.02 - 2.09 (m, 2H, 16-H), 2.10 (dt, J = 7.2 Hz, J = 7.2 Hz, 2H, 4-H), 2.12 (t, J = 7.8 Hz, 2H, 2-H), 2.70 (octet, J = 3.6 Hz, 1H, >N-CH<), 2.75 – 2.85 (ddd and t overlapping, 3H, 10-H and 7-H, especially 2.80, t, J = 6.6 Hz, 2H, 7-H), 2.87 (ddd, J = 15.0 Hz, J = 7.3 Hz, J = 6.6 Hz, 1H, 10-H), 3.46 (sextet, J = 7.5 Hz, 1H, 13-H), 5.20 - 5.30 (m, 4H, 11-H, 12-H, 14-H, 15-H), 5.31 - 5.43 (m, 4H, 5-H, 6-H, 8-H, 9-H), 5.51 (br s, 1H, >NH). ¹³C NMR (100 MHz, CDCl₃) δ 174.1 (C=O), 135.1 (C=C), 134.1 (C=C), 129.1 (C=C), 128.7 (C=C), 128.4 (C=C), 128.2 (C=C), 128.1 (C=C), 125.6 (C=C), 35.9 (-NH-CH<), 31.5, 30.5, 29.4, 27.5, 26.6, 25.8, 25.6, 25.4, 22.5, 22.0, 14.0, 6.6. Mass spectrum (EI) m/z (relative intensity) 357 (M⁺, 5), 300 (4), 286 (5), 232 (10), 117 (7), 175 (11), 147 (10), 133 (17), 119 (17), 107 (22), 99 (39), 93 (54), 57 (100); Exact mass (EI) calculated for C₂₄H₃₉NO, 357.3032; found, 357.3025. LC/MS analysis (Waters MicroMass ZQ system) showed purity 97% and retention time 6.1 min for the title compound.

(13*S*,5*Z*,8*Z*,11*Z*,14*Z*)-*N*-Cyclobutyl-13-methyleicosa-5,8,11,14-tetraenamide (4b). The synthesis was carried out as described for 4a, using 34a (24 mg, 0.08 mmol), fresh carbonyldiimidazole (37 mg, 0.226 mmol) and cyclobutyl amine (22 mg, 0.302 mmol) in dry THF (0.4 mL). The crude oil obtained after work up was purified by flash column chromatography on silica gel (16% acetone in hexane) and

gave **4b** (26 mg, 92 % yield) as a colorless oil. ¹H NMR (600 MHz, CDCl₃) δ 0.89 (t, J = 6.9 Hz, 3H, 20-H), 1.02 (d, J = 6.6 Hz, 3H, >CH-CH₃), 1.25 – 1.33 (m, 4H, 18-H, 19-H), 1.36 (sextet, J = 7.2 Hz, 2H, 17-H), 1.65 – 1.74 (m and quintet overlapping, 4H, cyclobutane ring and 3-H, especially 1.71, quintet, J = 7.2 Hz, 2H, 3-H), 1.78 – 1.86 (m, 2H, cyclobutane ring), 2.03 – 2.09 (m, 2H, 16-H), 2.10 (dt, J = 7.2 Hz, J = 7.2 Hz, 2H, 4-H), 2.13 (t, J = 7.2 Hz, 2H, 2-H), 2.30 - 2.38 (m, 2H, cyclobutane)ring), 2.75 - 2.85 (ddd and t overlapping, 3H, 10-H and 7-H, especially 2.80, t, J = 6.2 Hz, 2H, 7-H), 2.87 (ddd, J = 15.0 Hz, J = 7.4 Hz, J = 6.7 Hz, 1H, 10-H), 3.46 (sextet, J = 7.7 Hz, 1H, 13-H), 4.10 (sextet, J = 8.4 Hz, 1H, >N-CH<), 5.20 – 5.30 (m, 4H, 11-H, 12-H, 14-H, 15-H), 5.31 – 5.43 (m, 4H, 5-H, 6-H, 8-H, 9-H), 5.52 (br s, 1H, >NH). ¹³C NMR (75 MHz, CDCl₃) δ 171.8 (>C=O), 135.1 (C-12), 134.1 (C-14), 129.1 (C-8), 128.7 (C-5), 128.4 (C-6), 128.2 (C-15), 128.1 (C-9), 125.6 (C-11), 44.6 (-NH-CH<), 36.0 (C-2), 31.6 (C-18), 31.4 (cyclobutane ring), 30.5 (C-13), 29.4 (C-17), 27.5 (C-16), 26.6 (C-4), 25.8 (C-10), 25.6 (C-7), 25.4 (C-3), 22.6 (C-19), 22.0 (C-13-CH₃), 15.0 (cyclobutane ring), 14.1 (C-20); Mass spectrum (ESI) m/z (relative intensity) 372 (M+H1⁺, 100), 301 (5); Exact mass (ESI) calculated for C₂₅H₄₂NO (M+H]⁺), 372.3266; found, 372.3264. LC/MS analysis (Waters MicroMass ZQ system) showed purity 98% and retention time 6.1 min for the title compound.

(13*S*,5*Z*,8*Z*,11*Z*,14*Z*)-*N*-Cyclopentyl-13-methyleicosa-5,8,11,14-tetraenamide (4c). The synthesis was carried out as described for 4a, using 34a (24 mg, 0.08 mmol), fresh carbonyldiimidazole (37 mg, 0.226 mmol) and cyclopentyl amine (26 mg, 0.302 mmol) in dry THF (0.4 mL). The crude oil obtained after work up was purified by flash column chromatography on silica gel (20 % acetone in hexane) and gave 4c (25 mg, 85 % yield) as a colorless oil. ¹H NMR (600 MHz, CDCl₃) δ 0.88 (t, *J* = 7.2 Hz, 3H, 20-H), 1.02 (d, *J* = 6.6 Hz, 3H, >CH-CH₃), 1.24 – 1.39 (m, 8H, cyclopentane ring, 17-H, 18-H, 19-H), 1.56 – 1.62 (m, 2H, cyclopentane ring), 1.62 – 1.69 (m, 2H, cyclopentane ring), 1.70 (quintet, *J* = 7.5

Hz, 2H, 3-H), 1.99 (sextet, J = 6.3 Hz, 2H, cyclopentane ring), 2.03 – 2.09 (m, 2H, 16-H), 2.11 (dt, J = 7.3 Hz, J = 7.3 Hz, 2H, 4-H), 2.14 (t, J = 7.8 Hz, 2H, 2-H), 2.75 – 2.85 (ddd and t overlapping, 3H, 10-H and 7-H, especially 2.80, t, J = 6.0 Hz, 2H, 7-H), 2.87 (ddd, J = 15.0 Hz, J = 7.4 Hz, J = 6.7 Hz, 1H, 10-H), 3.46 (sextet, J = 7.8 Hz, 1H, 13-H), 4.21 (sextet, J = 7.2 Hz, 1H, >N-CH<), 5.20 – 5.30 (m, 4H, 11-H, 12-H, 14-H, 15-H), 5.31 – 5.43 (m, 5H, >NH, 5-H, 6-H, 8-H, 9-H). ¹³C NMR (75 MHz, CDCl₃) δ 172.32 (>C=0), 135.1 (C-12), 134.1 (C-14), 129.2 (C-8), 128.7 (C-5), 128.4 (C-6), 128.2 (C-15), 128.1 (C-9), 125.6 (C-11), 51.1 (-NH-CH<), 36.2 (C-2), 33.2 (cyclopentane ring), 31.6 (C-18), 30.5 (C-13), 29.4 (C-17), 27.5 (C-16), 26.6 (C-4), 25.8 (C-10), 25.6 (C-7 or C-3), 25.6 (C-3 or C-7), 23.7 (cyclopentane ring), 22.6 (C-19), 22.0 (C-13-*C*H₃), 14.1 (C-20); Mass spectrum (ESI) m/z (relative intensity) 386 (M+H1⁺, 100), 184 (9); Exact mass (ESI) calculated for C₂₆H₄₄NO (M+H1⁺), 386.3423; found, 386.3414. LC/MS analysis (Waters MicroMass ZQ system) showed purity 98% and retention time 6.1 min for the title compound.

(13S,5Z,8Z,11Z,14Z)-13-Methyl-*N*-(prop-2-yn-1-yl)eicosa-5,8,11,14-tetraenamide (4d). The synthesis was carried out as described for 4a, using 34a (12 mg, 0.04 mmol), fresh carbonyldiimidazole (18 mg, 0.113 mmol) and propargyl amine (8.3 mg, 0.151 mmol) in dry THF (0.2 mL). The crude oil obtained after work up was purified by flash column chromatography on silica gel (25 % acetone in hexane) and gave 4d (12 mg, 88 % yield) as a colorless oil. ¹H NMR (600 MHz, CDCl₃) δ 0.89 (t, *J* = 6.6 Hz, 3H, 20-H), 1.02 (d, *J* = 6.6 Hz, 3H, >CH-CH₃), 1.24 – 1.33 (m, 4H, 18-H, 19-H), 1.37 (sextet, *J* = 7.2 Hz, 2H, 17-H), 1.73 (quintet, *J* = 7.8 Hz, 2H, 3-H), 2.06 (nonet, *J* = 7.2 Hz, 2H, 16-H), 2.12 (dt, *J* = 7.2 Hz, *J* = 7.2 Hz, 2H, 4-H), 2.20 (t, *J* = 7.8 Hz, 2H, 2-H), 2.23 (t, *J* = 2.4 Hz, 1H, -C≡CH), 2.75 – 2.84 (ddd and t overlapping, 3H, 10-H and 7-H, especially 2.81, t, *J* = 6.0 Hz, 2H, 7-H), 2.87 (ddd, *J* = 15.0 Hz, *J* = 7.5 Hz, *J* = 6.2 Hz, 1H, 10-H), 3.46 (sextet, *J* = 7.8 Hz, 1H, 13-H), 4.05 (dd, *J* = 4.8 Hz, *J*

= 2.4 Hz, 2H, $-CH_2-C\equiv C$ -), 5.20 – 5.30 (m, 4H, 11-H, 12-H, 14-H, 15-H), 5.32 – 5.44 (m, 4H, 5-H, 6-H, 8-H, 9-H), 5.55 (br s, 1H, >NH). ¹³C NMR (75 MHz, CDCl₃) δ 172.3 (>C=O), 135.1 (C-12), 134.1 (C-14), 128.9 (C-8), 128.9 (C-5), 128.4 (C-6), 128.2 (C-15), 128.1 (C-9), 125.6 (C-11), 79.5 (-*C*=CH), 71.6 (-C=CH), 35.7 (C-2), 31.5 (C-18), 30.5 (C-13), 29.4 (C-17), 29.1 (-NH-CH₂-), 27.5 (C-16), 26.5 (C-4), 25.8 (C-10), 25.6 (C-7), 25.2 (C-3), 22.6 (C-19), 22.0 (C-13-CH₃), 14.0 (C-20); Mass spectrum (ESI) m/z (relative intensity) 356 (M+H1⁺, 100), 301 (10); Exact mass (ESI) calculated for C₂₄H₃₈NO (M+H1⁺), 356.2953; found, 356.2953. LC/MS analysis (Waters MicroMass ZQ system) showed purity 98% and retention time 6.0 min for the title compound.

(13S,5Z,8Z,11Z,14Z)-N-(2-Chloroethyl)-13-methyleicosa-5,8,11,14-tetraenamide The (**4e**). synthesis was carried out as described for 4a, using 34a (25 mg, 0.08 mmol), fresh carbonyldiimidazole (38 mg, 0.236 mmol) and a mixture of chloroethyl amine hydrochloride 37 mg, 0.314 mmol) and dry pyridine (0.3 mL) in THF (0.4 mL). The crude oil obtained after work up was purified by flash column chromatography on silica gel (20 % acetone in hexane) and gave 4e (27 mg, 89 % yield) as a colorless oil. ¹H NMR (600 MHz, CDCl₃) δ 0.89 (t, J = 6.7 Hz, 3H, 20-H), 1.02 (d, J = 6.6 Hz, 3H, >CH-CH₃), 1.24 – 1.33 (m, 4H, 18-H, 19-H), 1.36 (sextet, J = 7.2 Hz, 2H, 17-H), 1.73 (quintet, J = 7.8 Hz, 2H, 3-H), 2.06 (nonet, J = 6.6 Hz, 2H, 16-H), 2.12 (dt, J = 7.2 Hz, J = 7.2 Hz, 2H, 4-H), 2.22 (t, J = 7.8 Hz, 2-H), 2.76 –2.84 (ddd and t overlapping, 3H, 10-H and 7-H, especially 2.81, t, J = 6.0 Hz, 2H, 7-H), 2.87 (dd, J = 15.0 Hz, J = 7.5 Hz, J = 6.2 Hz, 1H, 10-H), 3.46 (sextet, J = 7.4 Hz, 1H, 13-H), 3.58 - 3.65(m and t overlapping, 4H, $>N-CH_2$ -, $-CH_2$ -Cl, especially 3.62, t, J = 4.8 Hz, 2H, $-CH_2$ -Cl), 5.20 – 5.31 (m, 4H, 11-H, 12-H, 14-H, 15-H), 5.33 - 5.44 (m, 4H, 5-H, 6-H, 8-H, 9-H), 5.84 (br s, 1H, >NH). ¹³C NMR (75 MHz, CDCl₃) δ 173.0 (>C=O), 135.1 (C-12), 134.1 (C-14), 129.0 (C-8), 128.9 (C-5), 128.4 (C-6), 128.2 (C-15), 128.1 (C-9), 125.6 (C-11), 44.2 (-CH₂Cl), 41.1 (-NH-CH₂-), 35.9 (C-2), 31.6 (C-

18), 30.5 (C-13), 29.5 (C-17), 27.5 (C-16), 26.6 (C-4), 25.8 (C-10), 25.6 (C-7), 25.4 (C-3), 22.6 (C-19), 22.0 (C-13-CH₃), 14.0 (C-20); Mass spectrum (ESI) m/z (relative intensity) 380 (M+Hl⁺, 100), 338 (15), 216 (12), 178 (15); Exact mass (ESI) calculated for $C_{23}H_{39}CINO$ (M+Hl⁺), 380.2720; found, 380.2703. LC/MS analysis (Waters MicroMass ZQ system) showed purity 98% and retention time 5.8 min for the title compound.

(13S,5Z,8Z,11Z,14Z)-20-Azido-N-cyclopropyl-13-methyleicosa-5,8,11,14-tetraenamide (**4f**). А solution of acid 44 (75 mg, 0.209 mmol), and dried carbonyldiimidazole (96 mg, 0.593 mmol) in dry THF (6.7 mL) at room temperature under an argon atmosphere, was stirred for 2 hours and then cyclopropylamine (0.089 mL, 2.965 mmol) was added. The reaction mixture was stirred for 2 hours and then diluted with water and ethyl acetate. The organic phase was separated, and the aqueous phase extracted with EtOAc. The combined organic layer was washed with brine, dried over MgSO₄ and concentrated under reduced pressure. The crude product obtained after work up was purified by flash column chromatography on silica gel (59:40:1 EtOAc: hexane: MeOH) and gave 62 mg (74 % yield) of **4f** as a colorless oil. IR (neat) 3276 (br, OH), 2927, 2093 (s, N₃), 1645, 1541, 1454, 1261, 720 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.45 – 0.50 (m, 2H, cyclopropyl ring), 0.73 – 0.79 (m, 2H, cyclopropyl ring), 1.01 (d, J = 6.5 Hz, 3H, >CH-CH₃), 1.34 – 1.42 (m, 4H, 18-H, 19-H), 1.60 (br quintet, J = 7.0Hz, 2H, 17-H), 1.71 (quintet, J = 7.5 Hz, 2H, 3-H), 2.07 – 2.14 (m, 6H, 2-H, 4-H and 16-H), 2.66 – 2.72 (m, 1H, -NH-CH<), 2.78 – 2.88 (m, 4H, 7-H, 10-H), 3.26 (t, J = 6.5 Hz, 2H, 20-H), 3.46 (ddq as sextet, J = 7.5 Hz, 1H, 13-H), 5.20 – 5.30 (m, 4H, 11-H, 12-H, 14-H, 15-H), 5.32 – 5.43 (m, 4H, 5-H, 6-H, 8-H, 9-H), 5.55 (br s, 1H, >NH). ¹³C NMR (100MHz, CDCl₃) δ 174.1 (>C=O), 134.9 (-CH=), 134.6 (-CH=), 129.1 (-CH=), 128.7 (-CH=), 128.3 (-CH=), 128.2 (-CH=), 127.6 (-CH=), 125.7 (-CH=), 51.4, 35.8, 30.5, 29.7, 29.2, 28.8, 27.3, 26.6, 26.4, 25.8, 25.6, 25.4, 22.5, 22.0 (C₁₃-Me), 6.61; Mass

spectrum (ESI) m/z (relative intensity) 400 (M⁺+H+1, 27), 399 (M⁺+H, 100), 372 (M⁺+H+1-N₂, 20),
371 (M⁺+H-N₂, 71). Exact mass (ESI) calculated for C₂₄H₃₉N₄O (M⁺+H), 399.3124; found, 399.3122.
LC/MS analysis (Waters MicroMass ZQ system) showed purity 98% and retention time 5.9 min for the title compound.

(13S,5Z,8Z,11Z,14Z)-N-Cyclopropyl-20-isothiocyanato-13-methyleicosa-5,8,11,14-tetraenamide

(4g). To a solution of 4f (30 mg, 0.074 mmol) in anhydrous THF (2 mL) was added triphenyl phosphine (58 mg, 0.222 mmol) and carbon disulfide (53 mg, 0.74 mmol) and the reaction mixture was stirred at room temperature for 48 hours. After completion, the reaction mixture was concentrated under vacuum and purified by flash column chromatography on silica gel (59:40:1 EtOAc: hexane: MeOH) and gave 30 mg of 4g as a viscous oil in 96 % yield. IR (neat) 3273, 2926, 2091 (s, NCS), 1643, 1536, 1453, 1347, 1021 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.45 – 0.50 (m, 2H, cyclopropyl ring), 0.73 – 0.79 (m, 2H, cyclopropyl ring), 1.01 (d, J = 6.5 Hz, 3H, >CH-CH₃), 1.34 – 1.42 (m, 4H, 18-H, 19-H), 1.60 (br quintet, J = 7.0 Hz, 2H, 17-H), 1.71 (quintet, J = 7.5 Hz, 2H, 3-H), 2.07 – 2.14 (m, 6H, 2-H, 4-H and 16-H), 2.66 – 2.72 (m, 1H, -NH-CH<), 2.78 – 2.88 (m, 4H, 7-H, 10-H), 3.46 (ddg as sextet, J = 7.5 Hz, 1H, 13-H), 3.51 (t, J = 6.5 Hz, 2H, 20-H), 5.20 – 5.30 (m, 4H, 11-H, 12-H, 14-H, 15-H), 5.32 – 5.43 (m, 4H, 5-H, 6-H, 8-H, 9-H), 5.55 (br s, 1H, >NH). ¹³C NMR (100MHz, CDCl₃) δ 174.1 (>C=O), 134.9 (C=C), 134.8 (C=C), 129.1 (C=C), 128.7 (C=C), 128.3 (C=C), 128.2 (C=C), 127.4 (C=C), 125.7 (C=C), 45.0, 35.9, 30.5, 30.3, 29.9, 29.7, 28.9, 27.2, 26.6, 26.2, 25.8, 25.6, 25.4, 22.6, 22.0, 6.6. Mass spectrum (ESI) m/z (relative intensity) 416 (M⁺+H+1, 28), 415 (M⁺+H, 100), 358 (8). Exact mass (ESI) calculated for C₂₅H₃₉N₂OS (M⁺+H), 413.3056; found, 413.3043. LC/MS analysis (Waters MicroMass ZQ system) showed purity 97% and retention time 5.8 min for the title compound.

Radioligand binding assays. The affinities (K_i) of the new compounds for rat CB1 receptor as well as for mouse and human CB2 receptors were obtained by using membrane preparations from rat brain or HEK293 cells expressing either mCB2 or hCB2 receptors, and [³H]CP-55,940 as the radioligand, as previously described.^{6, 26} Membrane pretreatment with PMSF was carried out as in our earlier work.⁶ Results from the competition assays were analyzed using nonlinear regression to determine the IC₅₀ values for the ligand.³³ K_i values were calculated from the IC₅₀ (Prism by GraphPad Software, Inc.). Each experiment was performed in triplicate and K_i values determined from three independent experiments and are expressed as the mean of the three values.

cAMP assay. HEK293 cells stably expressing rCB1 receptors were used for the studies.^{27, 34} The cAMP assay was carried out using PerkinElmer's Lance ultra cAMP kit following the protocol of the manufacturer. Briefly, the assays were carried out in 384-well plates using 1000-1500 cells/well. The cells were harvested with non-enzymatic cell dissociation reagent Versene, washed once with HBSS and resuspended in the stimulation buffer. The various concentrations of the test compound (5 μ L) in forskolin (2 μ M final concentration) containing stimulation buffer were added to the plate followed by the cell suspension (5 μ L). Cells were stimulated for 30 min at room temperature. Eu-cAMP tracer working solution (5 μ L) and Ulight-anti-cAMP working solution (5 μ L) were then added to the plate and incubated at room temperature for 60 minutes. The data were collected on a Perkin-Elmer Envision instrument. The EC₅₀ values were determined by non-linear regression analysis using GraphPad Prism software (GraphPad Software, Inc., San Diego, CA).

Stability in human (h) and rat (r) FAAH. We have preparations of expressed, purified rat (r) and human (h) FAAH for enzyme assays currently performed in our lab.³⁵⁻³⁶ FAAH is incubated with

individual compounds, or native substrate (AEA) for comparison for 30 min. Samples taken at various time points are diluted with acetonitrile to precipitate the proteins for LC-MS/MS analysis.³⁷⁻³⁸ For samples analyzed by LC-MS/MS, chromatographic separation was achieved using an Agilent Zorbax SB-CN column (2.1x50 mm, 5 mm) on a Finnigan TSQ Quantum Ultra triple quad mass spectrometer (Thermo Electron, San Jose CA) with an Agilent 1100 HPLC on the front end (Agilent Technologies, Wilmington DE) as previously described.³⁹ The mobile phase consisted of 10 mM ammonium acetate, pH 7.3 (A) and methanol (B) in a flow rate of 0.5 ml/min; the autosampler was kept at 4°C to prevent analyte degradation. Eluted peaks were ionized via atmospheric pressure chemical ionization (APCI) in MRM mode. Internal standards were used to quantify the analyte concentrations.

Stability in hMGL and hABHD6: Cloning and Expression of hMGL and hABHD6 proteins in E. coli cells: hMGL and hABHD6 were expressed in BL21 (DE3) E. coli cells following genes cloning into pET45 vector as we described earlier.⁴⁰ Briefly, a single E. coli BL21 (DE3) colony containing the plasmids with hMGL or hABHD6 gene was inoculated into 10 ml of Luria broth supplemented with ampicillin (100 μ g ml⁻¹) and grown overnight at 30 °C for hMGL and 37 °C for hABHD6 with shaking (250 rpm). The next morning, these 10 ml mixtures were used to inoculate 500 ml of fresh Luria brothampicillin medium and allowed to grow under the specified conditions (30 °C for hMGL and 20 °C for hABHD6) until the culture reached an OD₆₀₀ of 0.7–1.2, at which time expression was induced by adding 0.3 mM (final concentration) of isopropyl-β-D-thiogalactopyranoside. After 5-7 h induction, the cells were harvested by centrifugation, washed with PBS (phosphate-buffered saline) and either used immediately or stored at -80 °C. <u>Preparation of E. coli cells lysate containing hMGL or hABHD6</u> <u>protein</u>: An E. coli cell pellet (100 mg) containing the hMGL or hABHD6 protein was resuspended in 1 mL of lysis buffer (150 mM NaCl, 50 mM Tris, 1% Triton X-100, pH 8.0) and disrupted on ice using

five, 50 second sonication cycles (1s sonication bursts at 23 W power separated by 5 s intervals, Vibra-Cell 500W, Sonics, Newtown, CT). The lysate was rotated at 4 °C for 1 hour to complete extraction and solubilization of proteins from cells debris and then centrifuged at 20,000 x g for 10 min at 4 °C. *Stability assay*. hMGL or hABHD6 (0.5 μ g total protein) are incubated at 37°C with AMG315, or native substrate (2-AG) for comparison for 30 min. Samples taken at various time points (0, 2, 5, 10, 15, 20, 25 and 30 min) are diluted with acetonitrile to precipitate the proteins, vortexed, and certifuzed for HPLC analysis. For samples analyzed by HPLC, chromatographic separation was achieved using a Supelco Discovery C18 (4.6 x 250 mm) column on a Waters Alliance 2695 HPLC system. Mobile phase consisted of acetonitrile (A) and water with 5% acetonitrile (B). Gradient elution started with 5% A, transitioning to 95% A over ten minutes and held for ten minutes at 95% A before returning to starting conditions; run time was 23 minutes, the flow rate was 1 mL/min and UV detection was at 204 nm. External standards in acetonitrile were used to quantify the analyte concentrations.

Stability in mCOX-2. We have used a polarographic assay that measures oxygen consumption to investigate the endogenous AEA and 2-AG as well as key analogs as substrates of mCOX-2 activity.^{31, 41} *Enzyme preparation*: Murine cyclooxygenase-2 was expressed in baculovirus-insect cell expression system. A pvL-1393 plasmid bearing the cDNA of murine COX-2 were co-transferred with linearized BaculoGold DNA to generate the recombinant baculovirus. Protein expression was performed in Sf-9 insect cells by infection for 48 hours. The cell pellets were harvested, lysed and purified by sequential ion-exchange and size exclusion chromatography to greater than 95% purity.⁴¹ *Oxygen Consumption Assays*: Cyclooxygenase inhibition was monitored by O₂ consumption using a Clark-type O2 sensitive electrode (Hansatech Pentney, Norfolk, England). Calibration was achieved using a N₂ saturated solution to establish a zero O₂ level within the reaction chamber prior to experimental measurements.

All final 1-mL assay solutions contained 50 nM purified protein, 2 equivalents of hematin, 100 mM Tris-Cl pH 8.0, 5 mM phenol and 1% DMSO. The reaction was initiated by addition of substrates or test compounds in DMSO by airtight syringes. Final concentration of substrates and test compounds were 50 µM. Oxygen consumption was monitored using a Hansatech OXYG1 plus, connected to a DW1 oxygen electrode chamber controlled with Oxyview software (PP Systems Inc, MA). The rates were calculated based on the maximal first derivate of the oxygen concentration curve and normalized to the rates of arachidonic acid.

Molecular Modeling. *Conformational analysis*: A conformational analysis of the large number of conformations that can be adopted by the flexible molecules **3a** and **3c** was accomplished using the Conformational Memories (CM) technique.⁴²⁻⁴⁴ This method is based on the exploration of the possible low-free energy conformations of a flexible ligand via Monte Carlo/simulated annealing random walks employing the CHARMM (Chemistry at HARvard Molecular Mechanics) force field. This technique overcomes energy barriers efficiently and converges in a reasonable number of steps. Through CM, a complete sampling of the conformational space of **3a** and **3c** was accomplished. *Numbering system*. The Ballesteros–Weinstein numbering system has been used for numbering the corresponding GPCR amino acid residues. This numbering system is based on assignment of 0.50 to the most highly conserved residue in each transmembrane helix (TMH).⁴⁵ This number is preceded by the TMH number. According to this system, for instance, the most highly conserved residue in TMH6 is P6.50. The previous amino acid would be labeled 6.49, and the residue immediately after this would be labeled 6.51. When referring to a loop residue the absolute sequence number is given in parentheses.

Materials and methods for characterization of in vivo effects. Subjects. Adult male mice $(39 \pm 10 \text{ g})$ were used in this study. Wildtype CD1 mice or CB1 knockout (KO) mice on a CD1 background strain were used. Animals were single housed in a temperature-controlled facility with food and water ad libitum, and maintained on a 12 hour light/dark cycle. Mice were bred and genotyped in the Mackie lab. Behavioral testing was performed in the Hohmann lab. All the experimental procedures were approved by Bloomington Institutional Animal Care and Use Committee of Indiana University and followed the guidelines for the treatment of animals of the International Association for the Study of Pain (Zimmermann, 1983). Chemicals. AMG315, AM356 and anandamide (AEA) were dissolved in a vehicle of dimethysulfoxide (Sigma-Aldrich, St. Louis, MO), emulphor (Alkamuls EL 620L, Solvay, Princeton, NJ), ethanol (Sigma-Aldrich), and sterile saline (Aquilite System, Hospira Inc, Lake Forest, IL) at a ratio of 5:2:2:16, respectively. Drugs were delivered via i.p. injection in a volume of 5 ml/kg. CFA-Induced Inflammatory Nociception. A single intraplantar injection of mixed solution of complete Freund's adjuvant (CFA) and saline (at ratio of 1:1; 20 µl total volume) was delivered unilaterally into the plantar surface of the right hind paw. Animals were given 48 hours to fully develop inflammatory pain before pharmacologic manipulations. Assessment of Mechanical Allodynia. Mechanical paw withdrawal thresholds were determined as described previously.³² Animals were habituated in Plexiglass test chambers for at least 30 minutes prior to the testing. An electronic von Frey anesthesiometer with 90-g probe (IITC Life Science, Woodland Hills, CA) was used to determine the paw withdrawal threshold to mechanical stimulation of the hind paw. The mechanical paw withdrawal threshold was recorded in duplicate and averaged for each paw respectively. The mechanical paw withdrawal thresholds were measured at baseline (i.e. before CFA injection), 48 hours after CFA injection, and at 10, 30, 60 and 120 minutes after pharmacological manipulation. General behavioral *methods*. Methods for in vivo testing were similar to those described in our previously published work.

Approximately 48 h following unilateral intraplantar injection of CFA, mice were injected with vehicle, anandamide, methananadmide or AMG315. *Statistical Analysis*. Two-way mixed ANOVA was used to analyze the main effect of drug treatments, main effect of time course or pre/post injection, and the interaction between drug treatments and time. Bonferroni post hoc tests were performed for all pairwise comparisons. Graph-Pad Prism version 7.04 (GraphPad Software, San Diego, CA) were used for all analyses and figure generation.

ANCILLARY INFORMATION

Supporting Information

Experimental procedures and related references, spectroscopic, analytical, and physical data for all compounds. Molecular formula strings. PDB coordinates for **3a** and **3c**. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Authors

1. Alexandros Makriyannis (Ph.D)

Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA.

Tel.: +1-617-373-4200; fax: +1-617-373-7493; e-mail: a.makriyannis@northeastern.edu.

2. Spyros P. Nikas (Ph.D)

Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA.

Tel.: +1-617-373-7620; fax: +1-617-373-7493; e-mail: s.nikas@northeastern.edu.

Present Address

⁴P.M.: Consejo Superior de Investigaciones Cientificas, Instituto de Química Médica Calle Juan de la Cierva, 3, Madrid, ES 28006. E-mail: paulamlcr@gmail.com. Phone: (34) 91 562 2900.

ACKNOWLEDGMENTS

This work was supported by grants from the National Institute on Drug Abuse to A. M., DA009158 and DA007215.

ABREVIATIONS USED

CB1, cannabinoid receptor 1; CB2, cannabinoid receptor 2; AEA, anandamide; 2-AG, 2arachidonoylglycerol; eCBs, endocannabinoids; FAAH, fatty acid amide hydrolase; MGL, monoacylglycerol lipase; ABHD6, alpha/beta-Hydrolase domain containing 6; a brain hydrolase; COX-2, cyclooxygenases-2; LOXs, lipooxygenases; CNS, central nervous system; SAR, structure-activity relationship; HEK293, human embryonic kidney cell line; NMR, nuclear magnetic resonance; HPLC, High-Performance Liquid Chromatography; CFA, complete Freund's adjuvant.

REFERENCES

 Lu, H. C.; Mackie, K. An introduction to the endogenous cannabinoid system. *Biol. Psychiatry* 2016, 79 (7), 516-525.

3 4	2.	Jarai, Z.; Wagner, J. A.; Goparaju, S. K.; Wang, L.; Razdan, R. K.; Sugiura, T.; Zimmer, A. M.;
5 6		Bonner, T. I.; Zimmer, A.; Kunos, G. Cardiovascular effects of 2-arachidonoyl glycerol in
7 8		anesthetized mice. Hypertension 2000, 35 (2), 679-684.
9 10 11	3.	Rouzer, C. A.; Marnett, L. J. Mechanism of free radical oxygenation of polyunsaturated fatty
12 13		acids by cyclooxygenases. Chem. Rev. 2003, 103 (6), 2239-2304.
14 15 16	4.	Urquhart, P.; Nicolaou, A.; Woodward, D. F. Endocannabinoids and their oxygenation by
17 18		cyclo-oxygenases, lipoxygenases and other oxygenases. Biochim. Biophys. Acta 2015, 1851 (4),
19 20		366-376.
21 22 22	5.	Alhouayek, M.; Muccioli, G. G. COX-2-derived endocannabinoid metabolites as novel
23 24 25		inflammatory mediators. Trends Pharmacol. Sci. 2014, 35 (6), 284-292.
26 27	6.	Papahatjis, D. P.; Nahmias, V. R.; Nikas, S. P.; Schimpgen, M.; Makriyannis, A. Design and
28 29		synthesis of (13S)-methyl-substituted arachidonic acid analogues: templates for novel
30 31 32		endocannabinoids. Chem. Eur. J. 2010, 16 (13), 4091-4099.
33 34	7.	Hua, T.; Vemuri, K.; Nikas, S. P.; Laprairie, R. B.; Wu, Y.; Qu, L.; Pu, M.; Korde, A.; Jiang, S.;
35 36		Ho, J. H.; Han, G. W.; Ding, K.; Li, X.; Liu, H.; Hanson, M. A.; Zhao, S.; Bohn, L. M.;
37 38 20		Makriyannis, A.; Stevens, R. C.; Liu, Z. J. Crystal structures of agonist-bound human
40 41		cannabinoid receptor CB1. Nature 2017, 547 (7664), 468-471.
42 43	8.	Padgett, L. W.; Howlett, A. C.; Shim, J. Y. Binding mode prediction of conformationally
44 45		restricted anandamide analogs within the CB1 receptor. J. Mol. Signal. 2008, 3, 5.
46 47 48	9.	Reggio, P. H. Endocannabinoid structure-activity relationships for interaction at the
49 50		cannabinoid receptors. Prostaglandins Leukot. Essent. Fatty Acids 2002, 66 (2-3), 143-160.
51 52		
53 54 55		
56 57		
58 59		
60		ACS Paragon Plus Environment

- Tian, X.; Guo, J.; Yao, F.; Yang, D. P.; Makriyannis, A. The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer. *J. Biol. Chem.* 2005, 280 (33), 29788-29795.
- van der Stelt, M.; van Kuik, J. A.; Bari, M.; van Zadelhoff, G.; Leeflang, B. R.; Veldink, G. A.; Finazzi-Agro, A.; Vliegenthart, J. F.; Maccarrone, M. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. *J. Med. Chem.* 2002, 45 (17), 3709-3720.
 - Abadji, V.; Lin, S.; Taha, G.; Griffin, G.; Stevenson, L. A.; Pertwee, R. G.; Makriyannis, A. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. *J. Med. Chem.* **1994**, *37* (12), 1889-1893.
- Bourne, C.; Roy, S.; Wiley, J. L.; Martin, B. R.; Thomas, B. F.; Mahadevan, A.; Razdan, R. K. Novel, potent THC/anandamide (hybrid) analogs. *Bioorg. Med. Chem.* 2007, *15* (24), 7850-7864.
- Brizzi, A.; Brizzi, V.; Cascio, M. G.; Corelli, F.; Guida, F.; Ligresti, A.; Maione, S.; Martinelli, A.; Pasquini, S.; Tuccinardi, T.; Di Marzo, V. New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo. *J. Med. Chem.* 2009, *52* (8), 2506-2514.
- 15. Thakur, G. A.; Nikas, S. P.; Li, C.; Makriyannis, A. Structural requirements for cannabinoid receptor probes. *Handb. Exp. Pharmacol.* **2005**, (168), 209-246.
 - 16. Yao, F.; Li, C.; Vadivel, S. K.; Bowman, A. L.; Makriyannis, A. Development of novel tailmodified anandamide analogs. *Bioorg. Med. Chem. Lett.* **2008**, *18* (22), 5912-5915.

2		
- 3 4	17.	Shelnut, E. L.; Nikas, S. P.; Finnegan, D. F.; Chiang, N.; Serhan, C. N.; Makriyannis, A. Design
5 6		and synthesis of novel prostaglandin E2 ethanolamide and glycerol ester probes for the putative
7 8		prostamide receptor(s). Tetrahedron Lett. 2015, 56 (11), 1411-1415.
9 10 11	18.	Hua, T.; Vemuri, K.; Pu, M.; Qu, L.; Han, G. W.; Wu, Y.; Zhao, S.; Shui, W.; Li, S.; Korde, A.;
12 13		Laprairie, R. B.; Stahl, E. L.; Ho, J. H.; Zvonok, N.; Zhou, H.; Kufareva, I.; Wu, B.; Zhao, Q.;
14 15		Hanson, M. A.; Bohn, L. M.; Makriyannis, A.; Stevens, R. C.; Liu, Z. J. Crystal structure of the
16 17		human cannabinoid receptor CB1. Cell 2016, 167 (3), 750-762.
18 19 20	19.	Janero, D. R.; Korde, A.; Makriyannis, A. Ligand-assisted protein structure (LAPS): An
21 22		experimental paradigm for characterizing cannabinoid-receptor ligand-binding domains.
23 24		Methods Enzymol. 2017, 593, 217-235.
25 26 27	20.	Janero, D. R.; Yaddanapudi, S.; Zvonok, N.; Subramanian, K. V.; Shukla, V. G.; Stahl, E.;
27 28 29		Zhou, L.; Hurst, D.; Wager-Miller, J.; Bohn, L. M.; Reggio, P. H.; Mackie, K.; Makriyannis, A.
30 31		Molecular-interaction and signaling profiles of AM3677, a novel covalent agonist selective for
32 33		the cannabinoid 1 receptor. ACS Chem. Neurosci. 2015, 6 (8), 1400-1410.
34 35 36	21.	Khanolkar, A. D.; Abadji, V.; Lin, S.; Hill, W. A.; Taha, G.; Abouzid, K.; Meng, Z.; Fan, P.;
37 38		Makriyannis, A. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid
39 40		ligand. J. Med. Chem. 1996, 39 (22), 4515-4519.
41 42 43	22.	Nikas, S. P.; D'Souza, M.; Makriyannis, A. Enantioselective synthesis of (10S)- and (10R)-
44 45		methyl-anandamides. Tetrahedron 2012, 68 (31), 6329-6337.
46 47	23.	Finnegan, D. F.; Shelnut, E. L.; Nikas, S. P.; Chiang, N.; Serhan, C. N.; Makriyannis, A. Novel
48 49		tail and head group prostamide probes. Bioorg. Med. Chem. Lett. 2015, 25 (6), 1228-1231.
50 51 52		
53 54		
55 56		
57 58		
59 60		ACS Paragon Plus Environment

Hurst, D.; Wager-Miller, J.; Bohn, L. M.; Reggio, P. H.; Mackie, K.; Makriyannis, A. interaction and signaling profiles of AM3677, a novel covalent agonist selective for inoid 1 receptor. ACS Chem. Neurosci. 2015, 6 (8), 1400-1410. A. D.; Abadji, V.; Lin, S.; Hill, W. A.; Taha, G.; Abouzid, K.; Meng, Z.; Fan, P.; is, A. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid *Aed. Chem.* **1996,** *39* (22), 4515-4519. P.; D'Souza, M.; Makriyannis, A. Enantioselective synthesis of (10S)- and (10R)indamides. *Tetrahedron* **2012**, 68 (31), 6329-6337. D. F.; Shelnut, E. L.; Nikas, S. P.; Chiang, N.; Serhan, C. N.; Makriyannis, A. Novel ad group prostamide probes. *Bioorg. Med. Chem. Lett.* **2015**, 25 (6), 1228-1231. ACS Paragon Plus Environment

2	
3	
4	
5	
6	
7	
, o	
0	
9	
10	
11	
12	
13	
14	
15	
15	
16	
17	
18	
19	
20	
21	
22	
22	
23	
24	
25	
26	
27	
28	
29	
30	
20	
31	
32	
33	
34	
35	
36	
37	
20	
20	
39	
40	
41	
42	
43	
44	
45	
75 76	
40	
4/	
48	
49	
50	
51	
52	
52	
- 22	
54 	
55	
56	
57	
58	

60

1

24. Goutopoulos, A.; Fan, P.; Khanolkar, A. D.; Xie, X. Q.; Lin, S.; Makriyannis, A. Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. *Bioorg. Med. Chem.* **2001**, *9* (7), 1673-1684.

- Lang, W.; Qin, C.; Lin, S.; Khanolkar, A. D.; Goutopoulos, A.; Fan, P.; Abouzid, K.; Meng, Z.;
 Biegel, D.; Makriyannis, A. Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. *J. Med. Chem.* 1999, 42 (5), 896-902.
- Nikas, S. P.; Sharma, R.; Paronis, C. A.; Kulkarni, S.; Thakur, G. A.; Hurst, D.; Wood, J. T.; Gifford, R. S.; Rajarshi, G.; Liu, Y.; Raghav, J. G.; Guo, J. J.; Jarbe, T. U.; Reggio, P. H.; Bergman, J.; Makriyannis, A. Probing the carboxyester side chain in controlled deactivation (-)delta(8)-tetrahydrocannabinols. *J. Med. Chem.* 2015, 58 (2), 665-681.
- Kulkarni, S.; Nikas, S. P.; Sharma, R.; Jiang, S.; Paronis, C. A.; Leonard, M. Z.; Zhang, B.; Honrao, C.; Mallipeddi, S.; Raghav, J. G.; Benchama, O.; Jarbe, T. U. C.; Bergman, J.; Makriyannis, A. Novel C-ring-hydroxy-substituted controlled deactivation cannabinergic analogues. *J. Med. Chem.* 2016, *59* (14), 6903-6919.
- Nikas, S. P.; Alapafuja, S. O.; Papanastasiou, I.; Paronis, C. A.; Shukla, V. G.; Papahatjis, D. P.;
 Bowman, A. L.; Halikhedkar, A.; Han, X.; Makriyannis, A. Novel 1',1'-chain substituted hexahydrocannabinols: 9beta-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist. *J. Med. Chem.* 2010, *53* (19), 6996-7010.
- Li, C.; Xu, W.; Vadivel, S. K.; Fan, P.; Makriyannis, A. High affinity electrophilic and photoactivatable covalent endocannabinoid probes for the CB1 receptor. *J. Med. Chem.* 2005, 48 (20), 6423-6429.

2		
3 4	30.	Ogawa, G.; Tius, M. A.; Zhou, H.; Nikas, S. P.; Halikhedkar, A.; Mallipeddi, S.; Makriyannis,
5 6		A. 3'-Functionalized adamantyl cannabinoid receptor probes. J. Med. Chem. 2015, 58 (7), 3104-
7 8		3116.
9 10	31.	Kudalkar, S. N.; Nikas, S. P.; Kingsley, P. J.; Xu, S.; Galligan, J. J.; Rouzer, C. A.; Banerjee, S.;
11 12 13		Ji, L.; Eno, M. R.; Makriyannis, A.; Marnett, L. J. 13-Methylarachidonic acid is a positive
14 15		allosteric modulator of endocannabinoid oxygenation by cyclooxygenase. J. Biol. Chem. 2015,
16 17		290 (12), 7897-7909.
18 19	32.	Li, A. L.; Carey, L. M.; Mackie, K.; Hohmann, A. G. Cannabinoid CB2 agonist GW405833
20 21		suppresses inflammatory and neuropathic pain through a CB1 mechanism that is independent of
22 23 24		CB2 receptors in mice I Pharmacol Evo Ther 2017 362 (2) 296-305
25 26	22	Chara V. Dreeff, W. H. Deletienskie between the inhibition constant (Ki) and the
27 28	33.	Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (Ki) and the
29 30		concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction.
31 32		Biochem. Pharmacol. 1973, 22 (23), 3099-3108.
33 34	34.	Sharma, R.; Nikas, S. P.; Paronis, C. A.; Wood, J. T.; Halikhedkar, A.; Guo, J. J.; Thakur, G.
35 36		A.; Kulkarni, S.; Benchama, O.; Raghav, J. G.; Gifford, R. S.; Jarbe, T. U.; Bergman, J.;
37 38		Makriyannis, A. Controlled-deactivation cannabinergic ligands. J. Med. Chem. 2013, 56 (24),
39 40 41		10142-10157.
42 43	35.	Alapafuja, S. O.; Nikas, S. P.; Bharathan, I. T.; Shukla, V. G.; Nasr, M. L.; Bowman, A. L.;
44 45		Zvonok, N.; Li, J.; Shi, X.; Engen, J. R.; Makriyannis, A. Sulfonyl fluoride inhibitors of fatty
46 47		acid amide hydrolase. J. Med. Chem. 2012, 55 (22), 10074-10089.
48 49 50	36.	Patricelli, M. P.; Lashuel, H. A.; Giang, D. K.; Kelly, J. W.; Cravatt, B. F. Comparative
50 51 52		characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase:
53 54		
55 56		
57		

identification of the transmembrane domain as a site for oligomerization. *Biochemistry* **1998**, *37* (43), 15177-15187.

- Lang, W.; Qin, C.; Hill, W. A.; Lin, S.; Khanolkar, A. D.; Makriyannis, A. High-performance liquid chromatographic determination of anandamide amidase activity in rat brain microsomes. *Anal. Biochem.* 1996, 238 (1), 40-45.
- 38. Qin, C.; Lin, S.; Lang, W.; Goutopoulos, A.; Pavlopoulos, S.; Mauri, F.; Makriyannis, A. Determination of anandamide amidase activity using ultraviolet-active amine derivatives and reverse-phase high-performance liquid chromatography. *Anal. Biochem.* **1998**, *261* (1), 8-15.
- Williams, J.; Wood, J.; Pandarinathan, L.; Karanian, D. A.; Bahr, B. A.; Vouros, P.; Makriyannis, A. Quantitative method for the profiling of the endocannabinoid metabolome by LC-atmospheric pressure chemical ionization-MS. *Anal. Chem.* 2007, 79 (15), 5582-5593.
- Zvonok, N.; Williams, J.; Johnston, M.; Pandarinathan, L.; Janero, D. R.; Li, J.; Krishnan, S. C.;
 Makriyannis, A. Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification. *J. Proteome Res.* 2008, 7 (5), 2158-2164.
- Xu, S.; Hermanson, D. J.; Banerjee, S.; Ghebreselasie, K.; Clayton, G. M.; Garavito, R. M.; Marnett, L. J. Oxicams bind in a novel mode to the cyclooxygenase active site via a two-watermediated H-bonding Network. *J. Biol. Chem.* 2014, 289 (10), 6799-6808.
- 42. Guarnieri, F.; Weinstein, H. Conformational memories and the exploration of biologically relevant peptide conformations: An illustration for the gonadotropin-releasing hormone. *J. Am. Chem Soc.* **1996**, *118* (24), 5580-5589.

1 2 3 4 5 6	43.
7 8 9 10 11 12 13	44.
14 15 16 17 18 19	45.
20 21 22 23 24 25	
26 27 28 29 30 31	
32 33 34 35 36 37	
38 39 40 41 42 43	
44 45 46 47 48 49	
50 51 52 53 54 55	
56 57 58 59 60	

43. Whitnell, R. M.; Hurst, D. P.; Reggio, P. H.; Guarnieri, F. Conformational memories with variable bond angles: Uses in conformational analysis in homogeneous and heterogeneous environments. *Biophys. J.* **2007**, 566a-567a.

44. Wilson, S. R.; Guarnieri, F. Calculation of rotational states of flexible molecules using simulated annealing. *Tetrahedron Lett.* **1991**, *32* (30), 3601-3604.

45. Ballesteros, J.; Weinstein, H., Integrated Methods for the Construction of Three-Dimensional Models and Computational Probing of Structure-Function Relations in G Protein-Coupled Receptors. In *Methods in Neurosciences*, Stuart, C. S., Ed. Academic Press: San Diego, 1995; Vol. 25, pp 366-428.

3
4
5
6
0
/
8
9
10
11
12
13
14
15
16
10
17
18
19
20
21
22
23
24
25
25
20
27
28
29
30
31
32
33
34
35
36
27
2/
38
39
40
41
42
43
44
45
46
10
т, ЛО
40 40
49
50
51
52
53
54
55
56
57
58
50
72

1 2

Table 1. Affinities (K_i) of chiral-Me-AEAs (2) for CB1 and CB2 cannabinoid receptors (\pm 95% confidence limits).

		$(\mathbf{K_{i}, nM})^{\mathbf{a}}$			
compd	Structure	rCB1 without PMSF	rCB1 with PMSF	mCB2	hCB2
AEA	O N O H O H O H	>1,000	74 ± 13	>1,000	160 ± 27
AM11412 2f	S N H H H	>1,000	520 ± 33	>1,000	188 ± 15
AM11604 2e	C C C C C C C C C C C C C C C C C C C	326 ± 40	1.7 ± 0.1	7.5 ± 2.5	24.7 ± 5.6
AM9277 2c	S N H H H H	>1,000	>1,000	>1,000	>1,000
AM9278 2d		>1,000	>1,000	>1,000	>1,000
AM8141 2b	N R H H	>1,000	>1,000	>1,000	>1,000
AMG313 2a	о s H H H	>1,000	4.8 ± 1.3	137 ± 22	50.5 ± 6.5

^aAffinities for CB1 and CB2 receptors were determined using rat brain (CB1) or membranes from HEK293 cells expressing mouse or human CB2 receptors and [³H]CP-55,940 as the radioligand following previously described procedures.^{6, 26} Data were analyzed using nonlinear regression analysis. K_i values were obtained from three independent experiments run in duplicate and are expressed as the mean of the three values.

 Table 2. Functional potencies (EC₅₀) of novel chiral-Me-AEAs (2) for CB1 cannabinoid receptor (±

 95% confidence limits).
 rCB1

 compd Structure EC₅₀ (nM), ^aE_(max) (%)^b

 AEA

 Group of the structure of

Agonist No response AM11604 $4.8 \pm 1.2, 100\%$ **2e** Agonist AM8141 **2b** No response OH N' H **AMG313** 2a 13.2 ± 2.8, 88% .OH Agonist

^aFunctional potencies at rCB1 receptor were determined by measuring the decrease in forskolinstimulated cAMP levels.²⁷ EC₅₀ values were calculated using nonlinear regression analysis. Data are the average of two independent experiments run in triplicate. ^bForskolin stimulated cAMP levels were normalized to 100%. $E_{(max)}$ is the maximum inhibition of forskolin stimulated cAMP levels and is presented as the percentage of CP-55,940 response at 500 nM.

ACS Paragon Plus Environment

Table 3. Affinities (K_i) of chiral-di-Me-AEAs (3) for CB1 and CB2 cannabinoid receptors (\pm 95% confidence limits).

		$(\mathbf{K_{i}, nM})^{\mathrm{a}}$			
compd	Structure	rCB1 without PMSF	rCB1 with PMSF	mCB2	hCB2
AM11414 3e	S H H H H H	29.3 ± 3.1	21.4 ± 2.3	>1,000	120 ± 11
AM11605 3d	N R OH	4.6 ± 1.3	2.2 ± 0.8	19.8 ± 4.5	12.8 ± 2.9
AMG317 3c		>1,000	>1,000	>1,000	>1,000
AMG315 3a	O N R OH H H	7.8 ± 1.4	8.9 ± 2.1	653 ± 55	176 ± 28
AMG319 3b	N S O H O H O H	65 ± 9	83 ± 12	>1,000	286 ± 50
AM356		72 ± 13	37 ± 9	>1,000	220 ± 45

^aAffinities for CB1 and CB2 receptors were determined using rat brain (CB1) or membranes from HEK293 cells expressing mouse or human CB2 receptors and [³H]CP-55,940 as the radioligand following previously described procedures.^{6, 26} Data were analyzed using nonlinear regression analysis. K_i values were obtained from three independent experiments run in duplicate and are expressed as the mean of the three values.

rCB1

Table 4. Functional potencies (EC₅₀) of novel chiral-di-Me-AEAs (3) for CB1 cannabinoid receptor (\pm 95% confidence limits). compd Structure AM11414 3e AM11605 3d

 $EC_{50} (nM), ^{a}E_{(max)}(\%)^{b}$ classification $58.3 \pm 6.6, 98\%$ Agonist $28.4 \pm 4.1, 100\%$ Agonist **AMG315** $0.6 \pm 0.2, 76\%$ N R 3a Agonist

^aFunctional potencies at rCB1 receptor were determined by measuring the decrease in forskolinstimulated cAMP levels.²⁷ EC₅₀ values were calculated using nonlinear regression analysis. Data are the average of two independent experiments run in triplicate. ^bForskolin stimulated cAMP levels were normalized to 100%. E(max) is the maximum inhibition of forskolin stimulated cAMP levels and is presented as the percentage of CP-55,940 response at 500 nM.

Table 5. Affinities (K_i) of (13*S*)-Me-AAs (4) for CB1 and CB2 cannabinoid receptors (\pm 95% confidence limits).

		(K _i , nM) ^a			
compd	Structure	rCB1	rCB1	mCB2	hCB2
		without PMSF	with PMSF		
AMG311 4a		14.7 ± 5.3	1.5 ± 0.3	57.5 ± 6.7	4.3 ± 1.1
AMG327 4b		17.6 ± 7.8	23.1 ± 5.1	90 ± 10	6.8 ± 0.9
AMG328 4c		123 ± 12	79 ± 8	387 ± 35	139 ± 23
AMG326 4d		8.6 ± 3.1	4.3 ± 0.6	74 ± 6	11.2 ± 3.7
AMG329 4e		45.3 ± 8.4	3.9 ± 1.4	401 ± 58	10.4 ± 2.6
AM9279 4f	S S N3	10.5 ± 2.6	6.3 ± 0.7	13.3 ± 1.5	8.5 ± 1.1
AM9280 4g		20.3 ± 3.5	15.6 ± 2.1	47.7 ± 8.1	22.1 ± 3.1

^aAffinities for CB1 and CB2 receptors were determined using rat brain (CB1) or membranes from HEK293 cells expressing mouse or human CB2 receptors and [³H]CP-55,940 as the radioligand following previously described procedures.^{6, 26} Data were analyzed using nonlinear regression analysis. K_i values were obtained from three independent experiments run in duplicate and are expressed as the mean of the three values.

Table 6. Functional potencies (EC₅₀) of selected (13S)-Me-AAs (4) for CB1 cannabinoid receptor (± 95% confidence limits).

compd	Structure	$\frac{rCB1}{EC_{50} (nM), {}^{a}E_{(max)} (\%)^{b}}$ classification
AMG311 4a		0.3 ± 0.1, 88% Agonist
AMG327 4b		36.1 ± 5.2, 92% Agonist
AMG326 4d	CI S	10.4 ± 2.6, 89% Agonist
AM9279 4f	S S N3	1.9 ± 0.7, 85% Agonist

^aFunctional potencies at rCB1 receptor were determined by measuring the decrease in forskolinstimulated cAMP levels.²⁷ EC₅₀ values were calculated using nonlinear regression analysis. Data are the average of two independent experiments run in triplicate. ^bForskolin stimulated cAMP levels were normalized to 100%. E_(max) is the maximum inhibition of forskolin stimulated cAMP levels and is presented as the percentage of CP-55,940 response at 500 nM.

Table 7: Summary of metabolic/FAAH stabilities of AEA and representative chiral-Me-AEAs (2), chiral-di-Me-AEAs (3) and (13*S*)-Me-AAs (4) for FAAH.

Cmpd	rCB1 preparations	Rat (r) FAAH ²	Human (h) FAAH ²
	without PMSF ¹	t _{1/2} (min)	t _{1/2} (min)
AEA	Not stable	12.1^{3}	13.2^{3}
2f	Not stable	ND	ND
2e	Not stable	ND	ND
2a	Not stable	ND	13.5^{3}
3 a	Stable	ND	Stable for 30 min ³
3e	Stable	ND	ND
3d	Stable	stable for 30 min ³	stable for 30 min ³
4 a	Stable	ND	25.2^{3}
4b	Stable	ND	Stable for 30 min ³
4 d	Stable	ND	Stable for 30 min ³
4 c	Stable	ND	Stable for 30 min ³

¹Incubation for 1 hour at 30°C. ²Preparations of expressed and partially purified enzymes were used. ³LC-MS/MS method. ND: not determined.





- 57 58
- 59 60



Figure 1. Structures and pharmacophoric regions of the endocannabinoids AEA (1a) and 2-AG (1b).



Figure 2: Design and progression of novel chiral AEA probes.



Figure 3: Retrosynthetic analysis of chiral AEA analogs.



Figure 4: Oxygenation of arachidonic acid (AA), AEA, and key analogs by mCOX-2. The oxygen consumption was monitored using an oxygen electrode chamber as described in the experimental section.



Figure 5: (A) Dock of 3a at CB1. (B) 3c has steric overlaps at CB1. PDB coordinates are available for 3a and 3c in Supporting Information.



Figure 6: **AMG315 reduced CFA-induced mechanical allodynia**. (A) AEA (20 mg/kg i.p.) transiently increased the CFA-reduced mechanical paw withdrawal threshold at 10 minutes post injection only. (C) Both AMG315 (5 mg/kg i.p.) and AM356 (20 mg/kg i.p.) suppressed CFA-induced

mechanical allodynia. Anti-allodynic efficacy of AMG315 (5 mg/kg i.p.) was greater than that of AMG356 at 10 minutes post injection. Anti-allodynic effects were absent at 120 minutes post injection. (E) AMG315 (5 mg/kg i.p.) increase mechanical paw withdrawal thresholds in the CFA-injected paw of WT but not CB1 KO mice. (B) & (D) & (F) Pharmacological manipulations did not change the mechanical paw withdrawal threshold on the contralateral side. * p < 0.05 vs. vehicle group; ^ p < 0.05 vs. AM356; # p < 0.05 vs. baseline. BL: baseline.



Scheme 1. Synthesis of the chiral aldehyde fragments. Reagents and conditions: a) TBDPSCl, imidazole, CH₂Cl₂, 0 °C to RT, 1.5 h, 97-98 %; b) DIBAL-H, CH₂Cl₂, -110 °C, 20 min, 87-88 %.



Scheme 2. Synthesis of the tail fragment for C7-Me-AEAs. Reagents and conditions: a) Cs₂CO₃, NaI, CuI, DMF, RT, 2 h, 93%; b) Ni(OAc)₂, NaBH₄, ethylenediamine, H₂, MeOH, RT, 2 h, 96 %; c) CBr₄, Ph₃P, CH₂Cl₂, 0 °C, 30 min, 94 %; d) Ph₃P, CH₃CN, 70-75 °C, 5 days, 90%.



Scheme 3. Synthesis of (7*R*)- and (7*S*)-Me-AEAs. Reagents and conditions: a) KHMDS, THF, RT, 1 h, then 8a, 8b, -115 to 0 °C, 2 h, 73-75 %; b) (trimethylsilyl)diazomethane, Et₂O/MeOH, RT, 30 min; c) TBAF, THF, 0 °C to RT, 2 h, 73-75 % from 16a, 16b; d) Dess-Martin periodinane, CH₂Cl₂, 0 °C to RT, 1.5 h; e) 14, KHMDS, THF, 0 °C, 30 min, then 19a, 19b, -115 °C to -20 °C, 3 h, 69-71 % from alcohols 18a, 18b; f) LiOH, THF/H₂O, RT, 24 h, 94-96 %; g) TBDPSCl, imidazole, CH₃CN, 0 °C, 30 min, 97%; h) carbonyldiimidazole, THF, RT, 2 h, then 23, RT, 2 h, 95-97 %; i) TBAF, THF, 0 °C to RT, 1 h, 85-88 %.



Scheme 4. Synthesis of (13*R*)-Me-AEA. Reagents and conditions: a) KHMDS, THF, -78 °C to -60 °C, 20 min, then **8b**, -115 °C to 0 °C, 3 h, 91%; b) TBAF, THF, 0 °C to RT, 1 h, 91%; c) Dess-Martin periodinane, 0 °C to RT, 75 min; d) CH₃(CH₂)₅P⁺Ph₃Br⁻, KHMDS, THF, 0 °C, 40 min, then addition of **28**, -115 °C to -100 °C, 50 min, 65% from alcohol **27**; e) LiOH, THF/H₂O, RT, 24 h, 85%; f) carbonyldiimidazole, THF, RT, 2 h, then **23**, RT, 1 h, 93%; g) TBAF, THF, 0 °C to RT, 1.5 h, 89%.



Scheme 5. Synthesis of chiral di-Me-AEAs. Reagents and conditions: a) Dess-Martin periodinane, 0 °C to RT, 3h; b) PhO(CH₂)₄P⁺Ph₃ Br⁻, KHMDS, THF, 0 °C, 40 min, then addition of **32**, -115 °C to -100 °C, 50 min, 63% from alcohol **31**; c) LiOH, THF/H₂O, RT, 24 h, 87%; d) TBDPSCl, imidazole, CH₃CN, 0 °C, 30 min, 95%; e) carbonyldiimidazole, THF, RT, 2 h, then **36**, RT, 1 h, 85-92%; f) TBAF, THF, 0 °C to RT, 1.5 h, 80-87%.



Scheme 6. Synthesis of (13*S*)-Me-arachidonoyl amides. Reagents and conditions: a) carbonyldiimidazole, THF, RT, 2 h, then R-NH₂, RT, 1 h, 85-92%; b) TBDPSCl, imidazole, THF, 0 °C to RT, 1.5 h, 85%; c) Ph₃P, toluene, 60-63 °C, 5 days, 81%. d) Dess-Martin periodinane, 0 °C to RT, 3h; e) 40, KHMDS, THF, 0 °C, 40 min, then addition of 32, -115 °C to -100 °C, 1h, 64% from alcohol 31; f) TBAF, THF, 0 °C to RT, 2 h, 85%; g) DPPA, DBU, DMF, 120 °C, 2 h, 71%; h) LiOH, THF/H₂O, RT, 24 h, 95%; i) carbonyldiimidazole, THF, RT, 2 h, then cyclopropylamine, RT, 2 h, 74%; j) CS₂, PPh₃, THF, RT, 48 h, 96%.

TOC GRAPHIC



Chiral AEA probes: High affinity, potent CB agonists. Stable towards FAAH and COX-2